

# Yoshiya Tanaka

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2781484/yoshiya-tanaka-publications-by-year.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

621 papers	20,950 citations	65 h-index	124 g-index
777 ext. papers	25,721 ext. citations	4.2 avg, IF	7.08 L-index

#	Paper	IF	Citations
621	Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study.. <i>Scientific Reports</i> , <b>2022</b> , 12, 154	4.9	0
620	Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach.. <i>Nature Reviews Rheumatology</i> , <b>2022</b> ,	8.1	19
619	Relationship between blood glucose variability in ambulatory glucose profile and standardized continuous glucose monitoring metrics: Subanalysis of a prospective cohort study. <i>Diabetes, Obesity and Metabolism</i> , <b>2022</b> , 24, 82-93	6.7	0
618	Difficult-to-treat rheumatoid arthritis with respect to responsiveness to biologic/targeted synthetic DMARDs: a retrospective cohort study from the FIRST registry. <i>Clinical and Experimental Rheumatology</i> , <b>2022</b> , 40, 86-96	2.2	0
617	Association of Viral Infection With the Development and Pathogenesis of Systemic Lupus Erythematosus.. <i>Frontiers in Medicine</i> , <b>2022</b> , 9, 849120	4.9	2
616	Hypoglycemia induces vascular endothelial dysfunction in subjects with normal glucose tolerance.. <i>Scientific Reports</i> , <b>2022</b> , 12, 2598	4.9	1
615	Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry.. <i>Arthritis Research and Therapy</i> , <b>2022</b> , 24, 61	5.7	3
614	Dawn of Precision Medicine in Psoriatic Arthritis.. <i>Frontiers in Medicine</i> , <b>2022</b> , 9, 851892	4.9	0
613	'Not at target': prevalence and consequences of inadequate disease control in systemic lupus erythematosus-a multinational observational cohort study.. <i>Arthritis Research and Therapy</i> , <b>2022</b> , 24, 70	5.7	1
612	Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.. <i>Annals of the Rheumatic Diseases</i> , <b>2022</b> ,	2.4	6
611	Nailfold microvascular abnormalities are associated with a higher prevalence of pulmonary arterial hypertension in patients with MCTD.. <i>Rheumatology</i> , <b>2022</b> ,	3.9	0
610	Short-Term Prognostic Factors in Hospitalized Herpes Zoster Patients and Its Associated Cerebro-Cardiovascular Events: A Nationwide Retrospective Cohort in Japan.. <i>Frontiers in Medicine</i> , <b>2022</b> , 9, 843809	4.9	
609	Associations between continuous glucose monitoring-derived metrics and HbA1c in patients with type 2 diabetes mellitus.. <i>Diabetes Research and Clinical Practice</i> , <b>2022</b> , 109836	7.4	0
608	Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: a retrospective study.. <i>Arthritis Research and Therapy</i> , <b>2022</b> , 24, 86	5.7	0
607	Eplerenone Improves Vascular Endothelial Function in Patients with Primary Aldosteronism: A Pilot Study.. <i>Journal of UOEH</i> , <b>2021</b> , 43, 379-384	1.6	
606	Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	4
605	An enhanced mitochondrial function through glutamine metabolism in plasmablast differentiation in systemic lupus erythematosus. <i>Rheumatology</i> , <b>2021</b> ,	3.9	4

604	Benefit-Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , <b>2021</b> , 1	4.4	1
603	Association between ultrasound images and patient-reported outcomes in the treatment of rheumatoid arthritis: a retrospective study. <i>BMC Rheumatology</i> , <b>2021</b> , 5, 49	2.9	
602	Discovery of a novel IgG and FcγRIIB cross-linking antibody, ASP2713, and its potential application in the treatment of systemic lupus erythematosus. <i>International Immunopharmacology</i> , <b>2021</b> , 101, 108343	5.8	
601	Subclinical synovitis detected by magnetic resonance imaging and ultrasonography following clinical remission in patients with rheumatoid arthritis: A retrospective study. <i>Rheumatology &amp; Autoimmunity</i> , <b>2021</b> , 1, 7-15		0
600	Potential of B-cell-targeting therapy in overcoming multidrug resistance and tissue invasiveness associated with P-glycoprotein expressing-B cell compartments. <i>Immunological Medicine</i> , <b>2021</b> , 44, 142-151	3.7	2
599	Safety and efficacy of fostamatinib in rheumatoid arthritis patients with an inadequate response to methotrexate in phase II OSKIRA-ASIA-1 and OSKIRA-ASIA-1X study. <i>Rheumatology</i> , <b>2021</b> , 60, 2884-2895	3.9	6
598	Enlarged glycemic variability in sulfonylurea-treated well-controlled type 2 diabetics identified using continuous glucose monitoring. <i>Scientific Reports</i> , <b>2021</b> , 11, 4875	4.9	1
597	The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus. <i>Lancet Rheumatology, The</i> , <b>2021</b> ,	14.2	7
596	Estimation of treatment and prognostic factors of pneumocystis pneumonia in patients with connective tissue diseases. <i>RMD Open</i> , <b>2021</b> , 7,	5.9	6
595	Comparative Efficacy and Safety of Peficitinib Versus Tofacitinib and Baricitinib for Treatment of Rheumatoid Arthritis: A Systematic Review and Network Meta-Analysis. <i>Rheumatology and Therapy</i> , <b>2021</b> , 8, 729-750	4.4	3
594	Pathological role of activated mTOR in CXCR3+ memory B cells of rheumatoid arthritis. <i>Rheumatology</i> , <b>2021</b> , 60, 5452-5462	3.9	1
593	Managing Osteoporosis and Joint Damage in Patients with Rheumatoid Arthritis: An Overview. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	9
592	Safety and Effectiveness of Peficitinib (ASP015K) in Patients with Rheumatoid Arthritis: Final Results (32 Months of Mean Peficitinib Treatment) From a Long-Term, Open-Label Extension Study in Japan, Korea, and Taiwan. <i>Rheumatology and Therapy</i> , <b>2021</b> , 8, 425-442	4.4	3
591	Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis. <i>Arthritis Research and Therapy</i> , <b>2021</b> , 23, 86	5.7	5
590	A case of systemic lupus erythematosus with marked ascites due to idiopathic non-cirrhotic portal hypertension. <i>Modern Rheumatology Case Reports</i> , <b>2021</b> , 5, 285-291	0.4	0
589	Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 1130-1136	2.4	7
588	Effects of Denosumab in Japanese Patients With Rheumatoid Arthritis Treated With Conventional Antirheumatic Drugs: 36-month Extension of a Phase III Study. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 1663-1671	4.1	2
587	Stimulator of Interferon Genes-associated Vasculopathy with an Onset in Infancy Diagnosed after the Development of Atypical Pulmonary Lesions During Treatment as Juvenile Idiopathic Arthritis. <i>Internal Medicine</i> , <b>2021</b> , 60, 1109-1114	1.1	1

586	Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trials. <i>Modern Rheumatology</i> , <b>2021</b> , 1-11	3.3	4
585	Relationship between glycemic intraday variations evaluated in continuous glucose monitoring and HbA1c variability in type 2 diabetes: pilot study. <i>Diabetology and Metabolic Syndrome</i> , <b>2021</b> , 13, 45	5.6	1
584	The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan. <i>Drug Safety</i> , <b>2021</b> , 44, 711-722	5.1	3
583	Fatal hemoperitoneum due to rupture of mesenteric artery in remission state of microscopic polyangiitis, concomitant with severe hypertension and posterior reversible encephalopathy syndrome: an autopsy case report. <i>CEN Case Reports</i> , <b>2021</b> , 10, 549-558	1	0
582	Prevention of infective complications in systemic lupus erythematosus: A systematic literature review for the APLAR consensus statements. <i>International Journal of Rheumatic Diseases</i> , <b>2021</b> , 24, 880-895	2.3	2
581	Updated APLAR consensus statements on care for patients with rheumatic diseases during the COVID-19 pandemic. <i>International Journal of Rheumatic Diseases</i> , <b>2021</b> , 24, 733-745	2.3	8
580	Differentiation, functions, and roles of T follicular regulatory cells in autoimmune diseases. <i>Inflammation and Regeneration</i> , <b>2021</b> , 41, 14	10.9	6
579	Work Environment-related Stress Factors are Correlated with Diabetes Development in Workers with Impaired Glucose Tolerance: A 5-year Follow-up Study Using the Brief Job Stress Questionnaire (BJSQ). <i>Journal of UOEH</i> , <b>2021</b> , 43, 183-196	1.6	1
578	Validity of claims-based algorithms for selected cancers in Japan: Results from the VALIDATE-J study. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2021</b> , 30, 1153-1161	2.6	2
577	Serum TNF $\alpha$ levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study. <i>Arthritis Research and Therapy</i> , <b>2021</b> , 23, 154	5.7	2
576	Response to: 'Comment on 'Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial' by Tanaka ' by Berkhout. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, e173	2.4	
575	Clinical aspects in patients with rheumatoid arthritis complicated with lymphoproliferative disorders without regression after methotrexate withdrawal and treatment for arthritis after regression of lymphoproliferative disorders. <i>Modern Rheumatology</i> , <b>2021</b> , 31, 94-100	3.3	3
574	Case of autoimmune polyendocrine syndrome type 3 complicated with anti-N-methyl-D-aspartic acid-receptor encephalitis. <i>Journal of Diabetes Investigation</i> , <b>2021</b> , 12, 290-292	3.9	
573	A phase 2a, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral gonadotropin-releasing hormone antagonist, ASP1707, in postmenopausal female patients with rheumatoid arthritis taking methotrexate. <i>Modern Rheumatology</i> , <b>2021</b> , 31, 53-60	3.3	0
572	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 71-87	2.4	50
571	Conversion of T Follicular Helper Cells to T Follicular Regulatory Cells by Interleukin-2 Through Transcriptional Regulation in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 132-142	9.5	18
570	Rapidly progressive glomerulonephritis after introduction of certolizumab pegol: a case report. <i>Modern Rheumatology Case Reports</i> , <b>2021</b> , 5, 11-15	0.4	1
569	Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in Patients With Active Rheumatoid Arthritis With Inadequate Response to Methotrexate: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Study. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 587-595	9.5	3

568	RANKL as a therapeutic target of rheumatoid arthritis. <i>Journal of Bone and Mineral Metabolism</i> , <b>2021</b> , 39, 106-112	2.9	9
567	Human dendritic cell-derived osteoclasts with high bone resorption capacity and T cell stimulation ability. <i>Bone</i> , <b>2021</b> , 142, 115616	4.7	8
566	A pooled safety analysis of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis treated over a median of 2 years. <i>Modern Rheumatology</i> , <b>2021</b> , 31, 543-555	3.3	3
565	Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2). <i>Modern Rheumatology</i> , <b>2021</b> , 1-16	3.3	2
564	Efficacy of once-weekly teriparatide in patients with glucocorticoid-induced osteoporosis: the TOWER-GO study. <i>Journal of Bone and Mineral Metabolism</i> , <b>2021</b> , 39, 446-455	2.9	3
563	Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study. <i>Rheumatology</i> , <b>2021</b> , 60, 2256-2266	3.9	5
562	Lung transplantation resulted in marked improvement of autoimmunity and scleroderma in diffuse cutaneous systemic sclerosis: a case report. <i>Rheumatology</i> , <b>2021</b> , 60, e129-e131	3.9	
561	Osteoporosis case ascertainment strategies in European and Asian countries: a comparative review. <i>Osteoporosis International</i> , <b>2021</b> , 32, 817-829	5.3	7
560	Why remission is not enough: underlying disease mechanisms in RA that prevent cure. <i>Nature Reviews Rheumatology</i> , <b>2021</b> , 17, 135-144	8.1	18
559	Associations between urinary 6-sulfatoxymelatonin excretion and diabetic vascular complications or arteriosclerosis in patients with type 2 diabetes. <i>Journal of Diabetes Investigation</i> , <b>2021</b> , 12, 601-609	3.9	2
558	The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries. <i>Rheumatology</i> , <b>2021</b> , 60, 820-828	3.9	14
557	Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials. <i>Modern Rheumatology</i> , <b>2021</b> , 31, 1-12	3.3	19
556	Predictors of new bone erosion in rheumatoid arthritis patients receiving conventional synthetic disease-modifying antirheumatic drugs: Analysis of data from the DRIVE and DESIRABLE studies. <i>Modern Rheumatology</i> , <b>2021</b> , 31, 34-41	3.3	4
555	Response to tocilizumab and work productivity in patients with rheumatoid arthritis: 2-year follow-up of FIRST ACT-SC study. <i>Modern Rheumatology</i> , <b>2021</b> , 31, 42-52	3.3	1
554	2019 Diagnostic criteria for mixed connective tissue disease (MCTD): From the Japan research committee of the ministry of health, labor, and welfare for systemic autoimmune diseases. <i>Modern Rheumatology</i> , <b>2021</b> , 31, 29-33	3.3	7
553	Recent progress in treatments of rheumatoid arthritis: an overview of developments in biologics and small molecules, and remaining unmet needs.. <i>Rheumatology</i> , <b>2021</b> , 60, vi12-vi20	3.9	0
552	mRNA as a potential biomarker for exercise: interventional and cross-sectional research in healthy subjects. <i>Journal of Clinical Biochemistry and Nutrition</i> , <b>2021</b> , 69, 137-144	3.1	0
551	Glucose-lowering effects of 7-day treatment with SGLT2 inhibitor confirmed by intermittently scanned continuous glucose monitoring in outpatients with type 1 diabetes. A pilot study. <i>Endocrine Journal</i> , <b>2021</b> , 68, 361-369	2.9	1

550	Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE). <i>RMD Open</i> , <b>2021</b> , 7,	5.9	1
549	Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE). <i>Arthritis Research and Therapy</i> , <b>2021</b> , 23, 9	5.7	4
548	A phase 2 study of E6011, an anti-Fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying antirheumatic drugs. <i>Modern Rheumatology</i> , <b>2021</b> , 31, 783-789	3.3	4
547	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	10
546	Upadacitinib in Rheumatoid Arthritis: A Benefit-Risk Assessment Across a Phase III Program. <i>Drug Safety</i> , <b>2021</b> , 44, 515-530	5.1	13
545	Similarity of Response to Biologics Between Elderly-onset Rheumatoid Arthritis (EORA) and Non-EORA Elderly Patients: From the FIRST Registry. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 1655-1662	4.1	2
544	Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea. <i>RMD Open</i> , <b>2021</b> , 7,	5.9	4
543	Blood glucose dynamics during sleep in patients with obstructive sleep apnea and normal glucose tolerance: effects of CPAP therapy. <i>Sleep and Breathing</i> , <b>2021</b> , 1	3.1	1
542	Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , <b>2021</b> , 23, 221	5.7	1
541	Immune recognition of lysyl-tRNA synthetase and isoleucyl-tRNA synthetase by anti-OJ antibody-positive sera. <i>Journal of Autoimmunity</i> , <b>2021</b> , 122, 102680	15.5	3
540	Therapeutic perspectives on the metabolism of lymphocytes in patients with rheumatoid arthritis and systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , <b>2021</b> , 17, 1121-1130	5.1	0
539	Prophylaxis against pneumocystis pneumonia in rheumatoid arthritis patients treated with b/tsDMARDs: Insights from 3,787 cases in FIRST registry. <i>Rheumatology</i> , <b>2021</b> ,	3.9	3
538	Radiographic Progression of Structural Joint Damage Over 5 Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis: Results From RA-BEYOND. <i>Journal of Rheumatology</i> , <b>2021</b> ,	4.1	1
537	Clinical relevance of T follicular helper cells in systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , <b>2021</b> , 17, 1143-1150	5.1	2
536	Low Vitamin D Levels are Associated with Vascular Endothelial Dysfunction in Patients with Poorly Controlled Type 2 Diabetes: A Retrospective Study. <i>Journal of Atherosclerosis and Thrombosis</i> , <b>2021</b> ,	4	3
535	Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis-a comprehensive review. <i>Arthritis Research and Therapy</i> , <b>2021</b> , 23, 3	5.7	5
534	Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 848-858	2.4	32
533	Involvement of lncRNA IL21-AS1 in interleukin-2 and T follicular regulatory cell activation in systemic lupus erythematosus.. <i>Arthritis Research and Therapy</i> , <b>2021</b> , 23, 302	5.7	5



532	Treatment of rheumatoid arthritis after regression of lymphoproliferative disorders in patients treated with methotrexate: a retrospective, multi-center descriptive study. <i>Modern Rheumatology</i> , <b>2020</b> , 1-14	3.3	2
531	Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. <i>RMD Open</i> , <b>2020</b> , 6,	5.9	36
530	ASP5094, a humanized monoclonal antibody against integrin alpha-9, did not show efficacy in patients with rheumatoid arthritis refractory to methotrexate: results from a phase 2a, randomized, double-blind, placebo-controlled trial. <i>Arthritis Research and Therapy</i> , <b>2020</b> , 22, 252	5.7	5
529	Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , <b>2020</b> , 22, 115	5.7	5
528	P209 Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the select Phase 3 clinical programme. <i>Rheumatology</i> , <b>2020</b> , 59,	3.9	2
527	Interleukin-23 drives expansion of Thelper 17 cells through epigenetic regulation by signal transducer and activators of transcription 3 in lupus patients. <i>Rheumatology</i> , <b>2020</b> , 59, 3058-3069	3.9	6
526	Fulminant Type 1 Diabetes with Diversity in Peripheral Blood Lymphocytes: A Case Report. <i>Journal of UOEH</i> , <b>2020</b> , 42, 57-62	1.6	
525	Care for patients with rheumatic diseases during COVID-19 pandemic: A position statement from APLAR. <i>International Journal of Rheumatic Diseases</i> , <b>2020</b> , 23, 717-722	2.3	17
524	A review of upadacitinib in rheumatoid arthritis. <i>Modern Rheumatology</i> , <b>2020</b> , 30, 779-787	3.3	16
523	Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation. <i>Arthritis Research and Therapy</i> , <b>2020</b> , 22, 141	5.7	4
522	Systemic lupus erythematosus with repeated protein-losing enteropathy resulting from different pathological conditions: a case report. <i>Modern Rheumatology Case Reports</i> , <b>2020</b> , 4, 229-232	0.4	0
521	Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry. <i>Arthritis Research and Therapy</i> , <b>2020</b> , 22, 136	5.7	5
520	State-of-the-art treatment of systemic lupus erythematosus. <i>International Journal of Rheumatic Diseases</i> , <b>2020</b> , 23, 465-471	2.3	21
519	Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA). <i>Journal of Bone and Mineral Metabolism</i> , <b>2020</b> , 38, 522-532	2.9	8
518	Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan. <i>Arthritis Research and Therapy</i> , <b>2020</b> , 22, 47	5.7	14
517	Short-term effectiveness of ixekizumab to refractory psoriatic arthritis with spondyloarthritis: two case reports. <i>Modern Rheumatology Case Reports</i> , <b>2020</b> , 4, 176-180	0.4	1
516	Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study. <i>Arthritis Research and Therapy</i> , <b>2020</b> , 22, 41	5.7	5
515	A case of bone destruction caused by chronic non-bacterial osteomyelitis (CNO) successfully repaired with a tumour necrosis factor- $\alpha$ inhibitor, adalimumab. <i>Modern Rheumatology Case Reports</i> , <b>2020</b> , 4, 196-201	0.4	1

514	A case of eosinophilic granulomatosis with polyangiitis as a mimicker of IgG4-related disease. <i>Modern Rheumatology Case Reports</i> , <b>2020</b> , 4, 278-282	0.4	1
513	Correlation between serological biomarkers of extracellular matrix turnover and lung fibrosis and pulmonary artery hypertension in patients with systemic sclerosis. <i>International Journal of Rheumatic Diseases</i> , <b>2020</b> , 23, 532-539	2.3	7
512	Usefulness of the index calculated as the product of levels of fasting plasma glucose and hemoglobin A1c for insulinoma screening. <i>Endocrine Journal</i> , <b>2020</b> , 67, 509-513	2.9	2
511	Tumour necrosis factor alpha promotes secretion of 14-3-3 $\beta$ by inducing necroptosis in macrophages. <i>Arthritis Research and Therapy</i> , <b>2020</b> , 22, 24	5.7	8
510	Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study. <i>Rheumatology</i> , <b>2020</b> , 59, 2427-2434	3.9	35
509	Minodronate combined with alfacalcidol versus alfacalcidol alone for glucocorticoid-induced osteoporosis: a multicenter, randomized, comparative study. <i>Journal of Bone and Mineral Metabolism</i> , <b>2020</b> , 38, 511-521	2.9	3
508	Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis. <i>International Journal of Rheumatic Diseases</i> , <b>2020</b> , 23, 316-324	2.3	1
507	Methionine Commits Cells to Differentiate Into Plasmablasts Through Epigenetic Regulation of BTB and CNC Homolog 2 by the Methyltransferase EZH2. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 1143-1153	9.5	13
506	The additive effects of hydroxychloroquine to maintenance therapy with standard of care in patients with systemic lupus erythematosus. <i>International Journal of Rheumatic Diseases</i> , <b>2020</b> , 23, 549-558	2.3	4
505	Peficitinib for the treatment of rheumatoid arthritis: an overview from clinical trials. <i>Expert Opinion on Pharmacotherapy</i> , <b>2020</b> , 21, 1015-1025	4	9
504	Five Cases of IgG4-related Disease with Nasal Mucosa and Sinus Involvement. <i>Internal Medicine</i> , <b>2020</b> , 59, 1905-1911	1.1	3
503	Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study. <i>Rheumatology</i> , <b>2020</b> , 59, 3303-3313	3.9	25
502	Response to: 'Some concerns from Turkey' by Bilgin. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, e16	2.4	3
501	A refractory case of a male patient with neuropsychiatric systemic lupus erythematosus with various psychiatric symptoms and MRI observations. <i>Clinical Neuropsychopharmacology and Therapeutics</i> , <b>2020</b> , 11, 1-4	0.2	
500	Hyperparathyroidism Which Developed after Resection of a Fibroblast Growth Factor 23-producing Tumor. <i>Internal Medicine</i> , <b>2020</b> , 59, 2523-2527	1.1	
499	Mild Encephalitis/Encephalopathy with Reversible Splenic Lesions in SLE. <i>Internal Medicine</i> , <b>2020</b> , 59, 2439-2440	1.1	2
498	3) The Front Line of Treatments for Autoimmune Diseases. <i>The Journal of the Japanese Society of Internal Medicine</i> , <b>2020</b> , 109, 1748-1758	0	
497	IgG4-type Multiple Myeloma with Diffuse Enlargement of the Thyroid Requiring Differentiation from IgG4-related Disease. <i>Internal Medicine</i> , <b>2020</b> , 59, 711-714	1.1	1



496	Correlations Between Glycemic Parameters Obtained from Continuous Glucose Monitoring and Hemoglobin A1c and Glycoalbumin Levels in Type 2 Diabetes Mellitus. <i>Journal of UOEH</i> , <b>2020</b> , 42, 299-306	1.6	2
495	Two patients with mixed connective tissue disease complicated by pulmonary arterial hypertension showing contrasting responses to pulmonary vasodilators. <i>Modern Rheumatology Case Reports</i> , <b>2020</b> , 4, 253-261	0.4	1
494	Validity and responsiveness of the Work Functioning Impairment Scale (WFun) in rheumatoid arthritis patients: A multicenter prospective study. <i>Modern Rheumatology</i> , <b>2020</b> , 30, 821-827	3.3	5
493	First external validation of sensitivity and specificity of the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for idiopathic inflammatory myopathies with a Japanese cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 387-392	2.4	10
492	An autopsy case of a patient with systemic sclerosis who developed marked pulmonary hypertension because of pulmonary tumor thrombotic microangiopathy caused by gastric carcinoma. <i>Modern Rheumatology Case Reports</i> , <b>2020</b> , 4, 56-62	0.4	1
491	Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 94-102	2.4	7
490	Safety of baricitinib in East Asian patients with moderate-to-severe active rheumatoid arthritis: An integrated analysis from clinical trials. <i>International Journal of Rheumatic Diseases</i> , <b>2020</b> , 23, 65-73	2.3	10
489	Is precision medicine possible in rheumatic diseases? Lessons from selective use of targeted therapies in patients with psoriatic arthritis. <i>Expert Review of Clinical Immunology</i> , <b>2020</b> , 16, 199-206	5.1	4
488	Trial of Anifrolumab in Active Systemic Lupus Erythematosus. <i>New England Journal of Medicine</i> , <b>2020</b> , 382, 211-221	59.2	333
487	5-year remission rate after the discontinuation of adalimumab in patients with rheumatoid arthritis: Long-term follow-up results of the HONOR study. <i>Modern Rheumatology</i> , <b>2020</b> , 30, 799-806	3.3	1
486	In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors. <i>Rheumatology</i> , <b>2020</b> , 59, 1957-1968	3.9	9
485	The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-Related Disease. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 7-19	9.5	113
484	Critical roles of super-enhancers in the pathogenesis of autoimmune diseases. <i>Inflammation and Regeneration</i> , <b>2020</b> , 40, 16	10.9	6
483	P210 Efficacy and safety of filgotinib for patients with RA with inadequate response to methotrexate: FINCH1 primary outcome results. <i>Rheumatology</i> , <b>2020</b> , 59,	3.9	1
482	Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways. <i>Lupus Science and Medicine</i> , <b>2020</b> , 7,	4.6	14
481	Emerging Role of Fractalkine in the Treatment of Rheumatic Diseases. <i>ImmunoTargets and Therapy</i> , <b>2020</b> , 9, 241-253	9	5
480	Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction. <i>RMD Open</i> , <b>2020</b> , 6,	5.9	4
479	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1333-1339	2.4	16

478	Amiselimod, a sphingosine 1-phosphate receptor-1 modulator, for systemic lupus erythematosus: A multicenter, open-label exploratory study. <i>Lupus</i> , <b>2020</b> , 29, 1902-1913	2.6	3
477	Changes in endothelial function during educational hospitalization and the contributor to improvement of endothelial function in type 2 diabetes mellitus. <i>Scientific Reports</i> , <b>2020</b> , 10, 15384	4.9	1
476	Rheumatoid arthritis. <i>Inflammation and Regeneration</i> , <b>2020</b> , 40, 20	10.9	16
475	COVID-19 infection in patients with systemic lupus erythematosus: Data from the Asia Pacific Lupus Collaboration. <i>International Journal of Rheumatic Diseases</i> , <b>2020</b> , 23, 1255-1257	2.3	9
474	Systemic Lupus Erythematosus: Targeted literature review of the epidemiology, current treatment and disease burden in the Asia Pacific region. <i>Arthritis Care and Research</i> , <b>2020</b> ,	4.7	5
473	Severe pulmonary arterial hypertension and interstitial pneumonia related to systemic lupus erythematosus successfully treated with mycophenolate mofetil: A novel case report. <i>Lupus</i> , <b>2020</b> , 29, 1955-1960	2.6	3
472	A wide perspective of targeted therapies for precision medicine in autoimmune diseases. <i>Expert Review of Precision Medicine and Drug Development</i> , <b>2020</b> , 5, 447-453	1.6	2
471	Relationship between interstitial glucose variability in ambulatory glucose profile and standardized continuous glucose monitoring metrics; a pilot study. <i>Diabetology and Metabolic Syndrome</i> , <b>2020</b> , 12, 70	5.6	1
470	Enhanced Fatty Acid Synthesis Leads to Subset Imbalance and IFN- $\gamma$ Overproduction in T Helper 1 Cells. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 593103	8.4	3
469	Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials. <i>Modern Rheumatology</i> , <b>2020</b> , 30, 36-43	3.3	31
468	Safety and tolerability of sifalimumab, an anti-interferon- $\gamma$ monoclonal antibody, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study. <i>Modern Rheumatology</i> , <b>2020</b> , 30, 93-100	3.3	12
467	Safety and tolerability of anifrolumab, a monoclonal antibody targeting type I interferon receptor, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study. <i>Modern Rheumatology</i> , <b>2020</b> , 30, 101-108	3.3	16
466	Skeletal unloading reduces cluster of differentiation (CD) 38 expression in the bone marrow and osteoblasts of mice. <i>Journal of Orthopaedic Science</i> , <b>2020</b> , 25, 331-337	1.6	2
465	Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial. <i>Modern Rheumatology</i> , <b>2020</b> , 30, 313-320	3.3	5
464	Impaired expression of innate immunity-related genes in IgG4-related disease: A possible mechanism in the pathogenesis of IgG4-RD. <i>Modern Rheumatology</i> , <b>2020</b> , 30, 551-557	3.3	1
463	The development of quality indicators for systemic lupus erythematosus using electronic health data: A modified RAND appropriateness method. <i>Modern Rheumatology</i> , <b>2020</b> , 30, 525-531	3.3	4
462	Predictive value of serum amyloid A levels for requirement of concomitant methotrexate in tocilizumab initiation: A analysis of the SURPRISE study. <i>Modern Rheumatology</i> , <b>2020</b> , 30, 442-449	3.3	2
461	Focal Eosinophilic Myositis. <i>Internal Medicine</i> , <b>2020</b> , 59, 141	1.1	0

460	Sarilumab monotherapy or in combination with non-methotrexate disease-modifying antirheumatic drugs in active rheumatoid arthritis: A Japan phase 3 trial (HARUKA). <i>Modern Rheumatology</i> , <b>2020</b> , 30, 239-248	3.3	9
459	Effectiveness, safety, and methotrexate dose-tapering pattern over two years of treatment with adalimumab and 12 mg/week methotrexate for early rheumatoid arthritis: Results of the HAWK postmarketing surveillance study in Japan. <i>Modern Rheumatology</i> , <b>2020</b> , 30, 424-433	3.3	
458	A case of systemic lupus erythematosus in which Cushing's syndrome caused by adrenal adenoma accidentally occurred during long-term maintenance therapy with corticosteroids. <i>Modern Rheumatology Case Reports</i> , <b>2020</b> , 4, 34-38	0.4	1
457	The approach to precision medicine for the treatment of psoriatic arthritis. <i>Immunological Medicine</i> , <b>2020</b> , 43, 98-102	3.7	4
456	Associated factors of poor treatment outcomes in patients with giant cell arteritis: clinical implication of large vessel lesions. <i>Arthritis Research and Therapy</i> , <b>2020</b> , 22, 72	5.7	9
455	Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> ,	2.4	40
454	Soluble IL-6R promotes chondrogenic differentiation of mesenchymal stem cells to enhance the repair of articular cartilage defects using a rat model for rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , <b>2020</b> , 38, 670-679	2.2	2
453	Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study. <i>Clinical and Experimental Rheumatology</i> , <b>2020</b> , 38, 848-857	2.2	6
452	Response of thyrotropin-secreting pituitary tumors to preoperative lanreotide therapy. Report of two cases. <i>Neuroendocrinology Letters</i> , <b>2020</b> , 41, 10-16	0.3	
451	Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1305-1319	2.4	61
450	An Autopsy Case with Cerebral Hemorrhaging due to disseminated Aspergillosis During Glucocorticoid Therapy for Overlap Syndrome of Systemic Lupus Erythematosus and Systemic Sclerosis. <i>Internal Medicine</i> , <b>2019</b> , 58, 1023-1027	1.1	2
449	Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 878-891	9.5	38
448	Baricitinib for systemic lupus erythematosus - Authors' reply. <i>Lancet, The</i> , <b>2019</b> , 393, 402-403	4.0	3
447	Real-World Postmarketing Study of the Impact of Adalimumab Treatment on Work Productivity and Activity Impairment in Patients with Psoriatic Arthritis. <i>Advances in Therapy</i> , <b>2019</b> , 36, 691-707	4.1	5
446	Distinctive association of peripheral immune cell phenotypes with capillaroscopic microvascular patterns in systemic sclerosis. <i>Rheumatology</i> , <b>2019</b> , 58, 2273-2283	3.9	12
445	Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcet's disease. <i>Arthritis Research and Therapy</i> , <b>2019</b> , 21, 151	5.7	10
444	Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis. <i>RMD Open</i> , <b>2019</b> , 5, e000898	5.9	8
443	Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. <i>Lancet, The</i> , <b>2019</b> , 393, 2303-2311	4.0	143

442	A Study of the Vascular Endothelial Function in Patients with Type 2 Diabetes Mellitus and Rheumatoid Arthritis. <i>Internal Medicine</i> , <b>2019</b> , 58, 1383-1390	1.1	10
441	Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 890-898	2.4	13
440	Lymphocyte phenotype and its application to precision medicine in systemic autoimmune diseases. <i>Seminars in Arthritis and Rheumatism</i> , <b>2019</b> , 48, 1146-1150	5.3	14
439	Addition of canagliflozin to insulin improves glycaemic control and reduces insulin dose in patients with type 2 diabetes mellitus: A randomized controlled trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 2174-2179	6.7	1
438	Small Molecules <b>2019</b> , 629-637		
437	Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update. <i>Expert Review of Clinical Immunology</i> , <b>2019</b> , 15, 693-700	5.1	17
436	Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 899-907	2.4	54
435	Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan. <i>Arthritis Research and Therapy</i> , <b>2019</b> , 21, 79	5.7	19
434	Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia-Pacific region: Post-hoc analyses of pooled clinical study data. <i>International Journal of Rheumatic Diseases</i> , <b>2019</b> , 22, 1094-1106	2.3	7
433	Optimal Biologic Selection for Treatment of Psoriatic Arthritis: the Approach to Precision Medicine. <i>Current Rheumatology Reports</i> , <b>2019</b> , 21, 21	4.9	3
432	Usefulness of hemoglobin A1c and glycated albumin measurements for insulinoma screening: an observational case-control study. <i>BMC Cancer</i> , <b>2019</b> , 19, 174	4.8	4
431	Hypoglycemia Abrogates the Vascular Endothelial Protective Effect of Exenatide in Type 2 Diabetes Mellitus. <i>Diabetes Therapy</i> , <b>2019</b> , 10, 1127-1132	3.6	2
430	IL-6 and sIL-6R induces STAT3-dependent differentiation of human VSMCs into osteoblast-like cells through JMJD2B-mediated histone demethylation of RUNX2. <i>Bone</i> , <b>2019</b> , 124, 53-61	4.7	34
429	Expression of the genes encoding hypothalamic feeding-related neuropeptides in the streptozotocin-induced diabetic rats with variable hyperglycemia and hyperphagia. <i>Neuropeptides</i> , <b>2019</b> , 75, 34-40	3.3	1
428	Hypoglycemia in blood glucose level in type 2 diabetic Japanese patients by continuous glucose monitoring. <i>Diabetology and Metabolic Syndrome</i> , <b>2019</b> , 11, 18	5.6	1
427	Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: A subgroup analysis of a phase 3 randomized placebo-controlled trial. <i>Modern Rheumatology</i> , <b>2019</b> , 29, 452-460	3.3	3
426	l-Leucine influx through Slc7a5 regulates inflammatory responses of human B cells via mammalian target of rapamycin complex 1 signaling. <i>Modern Rheumatology</i> , <b>2019</b> , 29, 885-891	3.3	9
425	Modified- versus immediate-release tofacitinib in Japanese rheumatoid arthritis patients: a randomized, phase III, non-inferiority study. <i>Rheumatology</i> , <b>2019</b> , 58, 70-79	3.9	10

424	Effectiveness and safety of initiating adalimumab plus 12 mg/week methotrexate with adjustable dosing in biologic-naïve patients with early rheumatoid arthritis: HAWK study postmarketing surveillance in Japan. <i>Modern Rheumatology</i> , <b>2019</b> , 29, 572-580	3.3	6
423	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1151-1159	2.4	344
422	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 1400-1412	9.5	488
421	Glycolaldehyde-modified advanced glycation end-products inhibit differentiation of human monocytes into osteoclasts via upregulation of IL-10. <i>Bone</i> , <b>2019</b> , 128, 115034	4.7	15
420	Efficacy and Safety of Tofogliflozin on 24-h Glucose Profile Based on Continuous Glucose Monitoring: Crossover Study of Sodium-Glucose Cotransporter 2 Inhibitor. <i>Diabetes Technology and Therapeutics</i> , <b>2019</b> , 21, 385-392	8.1	2
419	A Case of Marine-Lenhart Syndrome with Predominance of Plummer Disease. <i>Journal of UOEH</i> , <b>2019</b> , 41, 165-170	1.6	3
418	Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes despite Multiple Disease-Modifying Antirheumatic Drug Therapy That Was Successfully Treated with Baricitinib: A Novel Case Report. <i>Case Reports in Rheumatology</i> , <b>2019</b> , 2019, 5293981	0.8	4
417	The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , <b>2019</b> , 21, 164	5.7	12
416	Treatment with Methotrexate and Intravenous Cyclophosphamide Pulse Therapy Regulates the P-gpCD4 Cell-related Pathogenesis in a Representative Patient with Refractory Proliferative Lupus Nephritis. <i>Internal Medicine</i> , <b>2019</b> , 58, 3173-3178	1.1	
415	3.State-of-the-art Internal Medicine in Joints and Bone. <i>The Journal of the Japanese Society of Internal Medicine</i> , <b>2019</b> , 108, 104a-111a	0	
414	3) Recent Progress in Cytokine-targeting Therapies in Rheumatic Diseases. <i>The Journal of the Japanese Society of Internal Medicine</i> , <b>2019</b> , 108, 393-400	0	
413	3. State-of-the-art Internal Medicine in Joints and Bone. <i>The Journal of the Japanese Society of Internal Medicine</i> , <b>2019</b> , 108, 1700-1712	0	
412	Mediastinal and axillar lymphadenopathy in patients with rheumatoid arthritis: prevalence and clinical significance. <i>Clinical Imaging</i> , <b>2019</b> , 55, 140-143	2.7	3
411	THU0193 EFFICACY OF TOFACITINIB MONOTHERAPY, TOFACITINIB WITH METHOTREXATE AND ADALIMUMAB WITH METHOTREXATE IN PATIENTS WITH EARLY (≤ YEARS) VS ESTABLISHED (>2 YEARS) RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF DATA FROM ORAL STRATEGY <b>2019</b> ,		3
410	Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3). <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1320-1332	2.4	65
409	Small Cell Lung Cancer Patient with Anti-transcriptional Intermediary Factor 1 Antibody Who Developed Dermatomyositis after Successful Chemoradiotherapy. <i>Internal Medicine</i> , <b>2019</b> , 58, 427-431	1.1	2
408	Safety and effectiveness of abatacept in Japanese non-elderly and elderly patients with rheumatoid arthritis in an all-cases post-marketing surveillance. <i>Modern Rheumatology</i> , <b>2019</b> , 29, 747-755	3.3	7
407	Type I and II interferons commit to abnormal expression of chemokine receptor on B cells in patients with systemic lupus erythematosus. <i>Clinical Immunology</i> , <b>2019</b> , 200, 1-9	9	5



406	The front line of research into immunoglobulin G4-related disease - Do autoantibodies cause immunoglobulin G4-related disease?. <i>Modern Rheumatology</i> , <b>2019</b> , 29, 214-218	3.3	18
405	Scleroderma in an ice-cream shop worker. <i>Rheumatology</i> , <b>2019</b> , 58, 1120-1121	3.9	1
404	Significance of nailfold videocapillaroscopy in patients with idiopathic inflammatory myopathies. <i>Rheumatology</i> , <b>2019</b> , 58, 120-130	3.9	14
403	Efficacy of denosumab with regard to bone destruction in prognostic subgroups of Japanese rheumatoid arthritis patients from the phase II DRIVE study. <i>Rheumatology</i> , <b>2019</b> , 58, 997-1005	3.9	12
402	Development of the Asia Pacific Lupus Collaboration cohort. <i>International Journal of Rheumatic Diseases</i> , <b>2019</b> , 22, 425-433	2.3	14
401	Response to: 'Tocilizumab in patients with adult-onset Still's disease refractory to glucocorticoid treatment' by Lee. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, e134	2.4	
400	The two cases of acute acalculous cholecystitis associated with systemic lupus erythematosus (SLE) presented different clinical aspects. <i>Modern Rheumatology Case Reports</i> , <b>2019</b> , 3, 114-118	0.4	1
399	Effectiveness and safety of hydroxychloroquine therapy with or without corticosteroid in patients with systemic lupus erythematosus. <i>International Journal of Rheumatic Diseases</i> , <b>2019</b> , 22, 434-442	2.3	8
398	Immunophenotype involved in IgG4-related disease. <i>Modern Rheumatology</i> , <b>2019</b> , 29, 226-230	3.3	10
397	Long-term safety and efficacy of weekly subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis who had an inadequate response to subcutaneous tocilizumab every other week: Results from the open-label extension of the SHINOBI study. <i>Modern Rheumatology</i> , <b>2019</b> , 29, 767-774	3.3	8
396	Clinical immunity in bone and joints. <i>Journal of Bone and Mineral Metabolism</i> , <b>2019</b> , 37, 2-8	2.9	23
395	Fatal Chronic Active Epstein-Barr Virus Infection in a Rheumatoid Arthritis Patient Treated with Abatacept. <i>Internal Medicine</i> , <b>2019</b> , 58, 585-591	1.1	5
394	Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data. <i>Modern Rheumatology</i> , <b>2019</b> , 29, 756-766	3.3	7
393	Efficacy and safety of sirukumab in Japanese patients with active rheumatoid arthritis who were refractory or intolerant to anti-tumor necrosis factor therapy: Subgroup analysis of a randomized, double-blind, multicenter, phase 3 study (SIRROUND-T). <i>Modern Rheumatology</i> , <b>2019</b> , 29, 306-313	3.3	1
392	Evaluation of oxygen extraction fraction in systemic lupus erythematosus patients using quantitative susceptibility mapping. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2019</b> , 39, 1648-1658	7.3	6
391	Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis. <i>Rheumatology</i> , <b>2019</b> , 58, 336-344	3.9	44
390	Intracranial vessel wall lesions in patients with systematic lupus erythematosus. <i>Journal of Magnetic Resonance Imaging</i> , <b>2018</b> , 48, 1237-1246	5.6	6
389	Comparison of efficacy of TNF inhibitors and abatacept in patients with rheumatoid arthritis; Adjusted with propensity score matching. <i>Clinical Immunology</i> , <b>2018</b> , 191, 67-74	9	6



388	Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus. <i>Modern Rheumatology</i> , <b>2018</b> , 28, 986-992	3.3	28
387	Splicing variant of augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 602-611	2.4	31
386	Clinical practice guideline for Sjögren's syndrome 2017. <i>Modern Rheumatology</i> , <b>2018</b> , 28, 383-408	3.3	27
385	Efficacy and safety of sirukumab in Japanese patients with moderate to severe rheumatoid arthritis inadequately controlled by disease modifying anti-rheumatic drugs: Subgroup analysis of a phase 3 study. <i>Modern Rheumatology</i> , <b>2018</b> , 28, 941-949	3.3	2
384	Relationship between disease activity and patient-reported outcomes in rheumatoid arthritis: Post hoc analyses of overall and Japanese results from two phase 3 clinical trials. <i>Modern Rheumatology</i> , <b>2018</b> , 28, 950-959	3.3	8
383	Determinants of Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity in patients with rheumatoid arthritis: A post hoc analysis of overall and Japanese results from phase 3 clinical trials. <i>Modern Rheumatology</i> , <b>2018</b> , 28, 960-967	3.3	10
382	Podocyte and endothelial cell injury lead to nephrotic syndrome in proliferative lupus nephritis. <i>Histopathology</i> , <b>2018</b> , 72, 1084-1092	7.3	6
381	Correlation of T follicular helper cells and plasmablasts with the development of organ involvement in patients with IgG4-related disease. <i>Rheumatology</i> , <b>2018</b> , 57, 514-524	3.9	34
380	A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 355-363	2.4	100
379	Relation Between Hypoglycemia and Glycemic Variability in Type 2 Diabetes Patients with Insulin Therapy: A Study Based on Continuous Glucose Monitoring. <i>Diabetes Technology and Therapeutics</i> , <b>2018</b> , 20, 140-146	8.1	17
378	Comparison of the Effects of Teneligliptin and Sitagliptin, Two Dipeptidyl Peptidase 4 Inhibitors with Different Half-Lives, on Glucose Fluctuation and Glucagon-Like Peptide-1 in Type 2 Diabetes Mellitus. <i>Journal of UOEH</i> , <b>2018</b> , 40, 1-9	1.6	2
377	Association Between Diabetic Microangiopathies and Glycemic Variability Assessed by Continuous Glucose Monitoring. <i>Journal of UOEH</i> , <b>2018</b> , 40, 11-18	1.6	2
376	Mechanisms and therapeutic targets for bone damage in rheumatoid arthritis, in particular the RANK-RANKL system. <i>Current Opinion in Pharmacology</i> , <b>2018</b> , 40, 110-119	5.1	50
375	Lymphocytic focus score is positively related to airway and interstitial lung diseases in primary Sjögren's syndrome. <i>Respiratory Medicine</i> , <b>2018</b> , 137, 95-102	4.6	28
374	JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial. <i>Nephrology Dialysis Transplantation</i> , <b>2018</b> , 33, 1950-1959	4.3	118
373	Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: A 52-week, randomized, single-blind, extension study. <i>Modern Rheumatology</i> , <b>2018</b> , 28, 20-29	3.3	28
372	Design characteristics of the Corrona Japan rheumatoid arthritis registry. <i>Modern Rheumatology</i> , <b>2018</b> , 28, 95-100	3.3	0
371	Twenty-four-hour variations in blood glucose level in Japanese type 2 diabetes patients based on continuous glucose monitoring. <i>Journal of Diabetes Investigation</i> , <b>2018</b> , 9, 75-82	3.9	6

370	Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritis. <i>Rheumatology</i> , <b>2018</b> , 57, 164-174	3.9	48
369	A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period. <i>Modern Rheumatology</i> , <b>2018</b> , 28, 76-84	3.3	14
368	Safety, pharmacokinetics, and efficacy of E6011, an anti-fractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis. <i>Modern Rheumatology</i> , <b>2018</b> , 28, 58-65	3.3	42
367	Relevance of P-glycoprotein on CXCR4 B cells to organ manifestation in highly active rheumatoid arthritis. <i>Modern Rheumatology</i> , <b>2018</b> , 28, 276-286	3.3	10
366	Economic impact of adalimumab treatment in Japanese patients with rheumatoid arthritis from the adalimumab non-interventional trial for up-verified effects and utility (ANOUVEAU) study. <i>Modern Rheumatology</i> , <b>2018</b> , 28, 39-47	3.3	3
365	Comparison of effects of anagliptin and alogliptin on serum lipid profile in type 2 diabetes mellitus patients. <i>Journal of Diabetes Investigation</i> , <b>2018</b> , 9, 360-365	3.9	9
364	RANKL: A therapeutic target for bone destruction in rheumatoid arthritis. <i>Modern Rheumatology</i> , <b>2018</b> , 28, 9-16	3.3	52
363	Characterization and Changes of Lymphocyte Subsets in Baricitinib-Treated Patients With Rheumatoid Arthritis: An Integrated Analysis. <i>Arthritis and Rheumatology</i> , <b>2018</b> , 70, 1923-1932	9.5	20
362	Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 1510	8.4	55
361	Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study. <i>Scientific Reports</i> , <b>2018</b> , 8, 10262	4.9	24
360	Hydroxychloroquine efficiently suppresses inflammatory responses of human class-switched memory B cells via Toll-like receptor 9 inhibition. <i>Clinical Immunology</i> , <b>2018</b> , 195, 1-7	9	38
359	Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , <b>2018</b> , 392, 222-231	40	243
358	Effect of subcutaneous tocilizumab treatment on work/housework status in biologic-naïve rheumatoid arthritis patients using inverse probability of treatment weighting: FIRST ACT-SC study. <i>Arthritis Research and Therapy</i> , <b>2018</b> , 20, 151	5.7	8
357	Use of mesenchymal stem cells seeded on the scaffold in articular cartilage repair. <i>Inflammation and Regeneration</i> , <b>2018</b> , 38, 4	10.9	21
356	Effects of hypergravity on the gene expression of the hypothalamic feeding-related neuropeptides in mice via vestibular inputs. <i>Peptides</i> , <b>2018</b> , 105, 14-20	3.8	3
355	Hyperparathyroidism-jaw Tumor Syndrome Confirmed by Preoperative Genetic Testing. <i>Internal Medicine</i> , <b>2018</b> , 57, 841-844	1.1	5
354	Risk Factors of Hypoglycemia in Patients with Type 2 Diabetes Mellitus: A Study Based on Continuous Glucose Monitoring. <i>Diabetes Technology and Therapeutics</i> , <b>2018</b> , 20, 603-612	8.1	17
353	Expansion of T follicular helper-T helper 1 like cells through epigenetic regulation by signal transducer and activator of transcription factors. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 1354-1361	2.4	33

352	Successful treatment with etanercept in a case of seronegative rheumatoid arthritis with corticosteroid/methotrexate-resistant pemphigus erythematosus. <i>Modern Rheumatology Case Reports</i> , <b>2018</b> , 2, 137-142	0.4	
351	Clinical efficacy, radiographic, and safety results of golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior therapy with disease-modifying antirheumatic drugs: Final results of the GO-MONO trial through week 120. <i>Modern Rheumatology</i> , <b>2018</b> , 28, 770-779	3.3	2
350	Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 348-354	2.4	181
349	Evaluation of the alternative classification criteria of systemic lupus erythematosus established by Systemic Lupus International Collaborating Clinics (SLICC). <i>Modern Rheumatology</i> , <b>2018</b> , 28, 642-648	3.3	11
348	Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials. <i>Modern Rheumatology</i> , <b>2018</b> , 28, 583-591	3.3	26
347	B cell phenotypes, signaling and their roles in secretion of antibodies in systemic lupus erythematosus. <i>Clinical Immunology</i> , <b>2018</b> , 186, 21-25	9	17
346	Glycemic Profiling in Patients with Drug-Naïve Type 2 Diabetes by Continuous Glucose Monitoring. <i>Journal of UOEH</i> , <b>2018</b> , 40, 287-297	1.6	
345	The role of nailfold videocapillaroscopy in patients with systemic sclerosis. <i>Immunological Medicine</i> , <b>2018</b> , 41, 113-119	3.7	7
344	Regulatory Mechanism of The Induction of Regulatory T Cells through Growth Factors Released by Human Mesenchymal Stem Cells. <i>Critical Reviews in Immunology</i> , <b>2018</b> , 38, 471-478	1.8	1
343	Abatacept in combination with methotrexate in Japanese biologic-naïve patients with active rheumatoid arthritis: a randomised placebo-controlled phase IV study. <i>RMD Open</i> , <b>2018</b> , 4, e000813	5.9	6
342	Th22 Cells Promote Osteoclast Differentiation Production of IL-22 in Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 2901	8.4	35
341	The Effects of Mitiglinide and Repaglinide on Postprandial Hyperglycemia in Patients Undergoing Methylprednisolone Pulse Therapy. <i>Internal Medicine</i> , <b>2018</b> , 57, 65-70	1.1	5
340	Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 1720-1729	2.4	83
339	Relevance of interferon-gamma in pathogenesis of life-threatening rapidly progressive interstitial lung disease in patients with dermatomyositis. <i>Arthritis Research and Therapy</i> , <b>2018</b> , 20, 240	5.7	20
338	Up-Regulation of TLR7-Mediated IFN- $\alpha$ Production by Plasmacytoid Dendritic Cells in Patients With Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 1957	8.4	31
337	Disease severity and economic burden in Japanese patients with systemic lupus erythematosus: A retrospective, observational study. <i>International Journal of Rheumatic Diseases</i> , <b>2018</b> , 21, 1609-1618	2.3	16
336	Risk Factors for Hypoglycemic Coma: A Study of 33 Patients on Insulin Therapy Who Were Transported to the Hospital by Ambulance. <i>Internal Medicine</i> , <b>2018</b> , 57, 2923-2927	1.1	
335	IgG4-related Pleuritis with Elevated Adenosine Deaminase in Pleural Effusion. <i>Internal Medicine</i> , <b>2018</b> , 57, 2251-2257	1.1	17

334	Successful Management of Pregnancy in a Patient with Systemic Lupus Erythematosus-associated Pulmonary Arterial Hypertension. <i>Internal Medicine</i> , <b>2018</b> , 57, 1655-1659	1.1	1
333	Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study). <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 57, 1668-1675	2.4	32
332	Increased remodelling of interstitial collagens and basement membrane is suppressed by treatment in patients with rheumatoid arthritis: serological evaluation of a one-year prospective study of 149 Japanese patients. <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36, 462-470	2.2	5
331	Impact of Adalimumab on Work Productivity and Activity Impairment in Japanese Patients with Rheumatoid Arthritis: Large-Scale, Prospective, Single-Cohort ANOUEAU Study. <i>Advances in Therapy</i> , <b>2017</b> , 34, 686-702	4.1	15
330	Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 1253-1262	2.4	257
329	Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 1348-1356	2.4	25
328	Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study. <i>Lancet, The</i> , <b>2017</b> , 389, 1206-1217	4.0	78
327	Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 652-662	59.2	427
326	Discontinuation of tofacitinib after achieving low disease activity in patients with rheumatoid arthritis: a multicentre, observational study. <i>Rheumatology</i> , <b>2017</b> , 56, 1293-1301	3.9	14
325	Metabolic Reprogramming Commits Differentiation of Human CD27IgD B Cells to Plasmablasts or CD27IgD Cells. <i>Journal of Immunology</i> , <b>2017</b> , 199, 425-434	5.3	47
324	Peripheral Immunophenotyping Identifies Three Subgroups Based on T Cell Heterogeneity in Lupus Patients. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 2029-2037	9.5	45
323	The occurrence of hypertrophic pachymeningitis with infiltration of IgG4-positive plasma cells and with different aetiology: report of three cases. <i>Modern Rheumatology Case Reports</i> , <b>2017</b> , 1, 108-112	0.4	0
322	Low disease activity for up to 3 years after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 Study. <i>Arthritis Research and Therapy</i> , <b>2017</b> , 19, 56	5.7	11
321	Determinants of hemoglobin A1c level in patients with type 2 diabetes after in-hospital diabetes education: A study based on continuous glucose monitoring. <i>Journal of Diabetes Investigation</i> , <b>2017</b> , 8, 314-320	3.9	7
320	Enlarged perivascular spaces are associated with the disease activity in systemic lupus erythematosus. <i>Scientific Reports</i> , <b>2017</b> , 7, 12566	4.9	14
319	The Effects of Pioglitazone on Bone Formation and Resorption Markers in Type 2 Diabetes Mellitus. <i>Internal Medicine</i> , <b>2017</b> , 56, 1301-1306	1.1	5
318	Early effects of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes: study based on continuous glucose monitoring. <i>Diabetology and Metabolic Syndrome</i> , <b>2017</b> , 9, 60	5.6	8
317	Comparative analysis of the effects of alogliptin and vildagliptin on glucose metabolism in type 2 diabetes mellitus. <i>Endocrine Journal</i> , <b>2017</b> , 64, 179-189	2.9	5

316	Efficacy of Intravenous Cyclophosphamide Pulse Therapy for P-Glycoprotein-expressing B Cell-associated Active True Renal Lupus Vasculitis in Lupus Nephritis. <i>Internal Medicine</i> , <b>2017</b> , 56, 1575-1580	1.1	1
315	Clinical Features of Patients with Basedow's Disease and High Serum IgG4 Levels. <i>Internal Medicine</i> , <b>2017</b> , 56, 1009-1013	1.1	9
314	Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 1960-1968	9.5	129
313	Remission induction by Raising the dose of Remicade in RA (RRRR) study: Rationale and study protocol for a randomized controlled trial comparing for sustained clinical remission after discontinuation of infliximab in patients with rheumatoid arthritis. <i>Contemporary Clinical Trials</i> , <b>2017</b> , 64, 54-61	1.8	4
312	Induction of Regulatory T Cells and Its Regulation with Insulin-like Growth Factor/Insulin-like Growth Factor Binding Protein-4 by Human Mesenchymal Stem Cells. <i>Journal of Immunology</i> , <b>2017</b> , 199, 1616-1625	5.3	38
311	Anti-PD-1 Antibody Therapy Induces Hashimoto's Disease with an Increase in Peripheral Blood Follicular Helper T Cells. <i>Thyroid</i> , <b>2017</b> , 27, 1335-1336	6.2	9
310	Rheumatoid arthritis: DMARD de-escalation - let the patient guide you. <i>Nature Reviews Rheumatology</i> , <b>2017</b> , 13, 637-638	8.1	11
309	Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 1853-1861	2.4	54
308	A case of rheumatoid arthritis treated with infliximab who developed disseminated <i>Penicillium marneffei</i> infection after visit to Thailand. <i>Modern Rheumatology Case Reports</i> , <b>2017</b> , 1, 43-48	0.4	3
307	Genome-wide Association Study of Idiopathic Osteonecrosis of the Femoral Head. <i>Scientific Reports</i> , <b>2017</b> , 7, 15035	4.9	17
306	A multicenter phase II prospective clinical trial of glucocorticoid for patients with untreated IgG4-related disease. <i>Modern Rheumatology</i> , <b>2017</b> , 27, 849-854	3.3	43
305	Factors influencing inter-day glycemic variability in diabetic outpatients receiving insulin therapy. <i>Journal of Diabetes Investigation</i> , <b>2017</b> , 8, 69-74	3.9	17
304	Efficacy and safety of tabalumab plus standard of care in Japanese patients with active systemic lupus erythematosus: Subgroup analyses of the ILLUMINATE-1 study. <i>Modern Rheumatology</i> , <b>2017</b> , 27, 284-291	3.3	6
303	Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab. <i>Modern Rheumatology</i> , <b>2017</b> , 27, 237-245	3.3	46
302	Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naïve patients with rheumatoid arthritis: The FIRST Bio study. <i>Modern Rheumatology</i> , <b>2017</b> , 27, 217-226	3.3	23
301	Role of P-glycoprotein on CD69CD4 cells in the pathogenesis of proliferative lupus nephritis and non-responsiveness to immunosuppressive therapy. <i>RMD Open</i> , <b>2017</b> , 3, e000423	5.9	5
300	Abatacept therapy reduces CD28+CXCR5+ follicular helper-like T cells in patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35, 562-570	2.2	16
299	Analysis of bone metabolism during early stage and clinical benefits of early intervention with alendronate in patients with systemic rheumatic diseases treated with high-dose glucocorticoid: Early Diagnosis and Treatment of Osteoporosis in Japan (EDITOR-J) study. <i>Journal of Bone and Mineral Metabolism</i> , <b>2016</b> , 34, 646-654	2.9	13



298	Quantitative susceptibility mapping in patients with systemic lupus erythematosus: detection of abnormalities in normal-appearing basal ganglia. <i>European Radiology</i> , <b>2016</b> , 26, 1056-63	8	14
297	Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy. <i>Modern Rheumatology</i> , <b>2016</b> , 26, 80-6	3.3	28
296	Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis. <i>BioDrugs</i> , <b>2016</b> , 30, 407-419.	9.9	39
295	Stopping tumour necrosis factor-targeted biological DMARDs in rheumatoid arthritis. <i>Rheumatology</i> , <b>2016</b> , 55, ii15-ii22	3.9	16
294	Detrimental effects of high-fat diet loading on vascular endothelial function and therapeutic efficacy of ezetimibe and statins in patients with type 2 diabetes. <i>Endocrine Journal</i> , <b>2016</b> , 63, 431-40	2.9	9
293	BAFF- and APRIL-targeted therapy in systemic autoimmune diseases. <i>Inflammation and Regeneration</i> , <b>2016</b> , 36, 6	10.9	24
292	Baricitinib for the treatment of rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , <b>2016</b> , 12, 911-9	5.1	28
291	Rationale and design of Diabetes Prevention with active Vitamin D (DPVD): a randomised, double-blind, placebo-controlled study. <i>BMJ Open</i> , <b>2016</b> , 6, e011183	3	10
290	Response to Dr Minota's Letter to the Editor of Modern Rheumatology Regarding a Study of Tofacitinib in Japanese Patients with Rheumatoid Arthritis. <i>Modern Rheumatology</i> , <b>2016</b> , 26, 318-9	3.3	
289	Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. <i>Arthritis Research and Therapy</i> , <b>2016</b> , 18, 34	5.7	90
288	Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study). <i>Rheumatology and Therapy</i> , <b>2016</b> , 3, 129-141	4.1	3
287	B-cell subsets, signaling and their roles in secretion of autoantibodies. <i>Lupus</i> , <b>2016</b> , 25, 850-6	2.6	37
286	Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , <b>2016</b> , 12, 1047-57	5.1	27
285	Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , <b>2016</b> , 26, 491-8	3.3	53
284	Association of plasmacytoid dendritic cells with B cell infiltration in minor salivary glands in patients with Sjögren's syndrome. <i>Modern Rheumatology</i> , <b>2016</b> , 26, 716-24	3.3	18
283	Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 1057-64	2.4	101
282	Safety, pharmacokinetics, and pharmacodynamics of epratuzumab in Japanese patients with moderate-to-severe systemic lupus erythematosus: Results from a phase 1/2 randomized study. <i>Modern Rheumatology</i> , <b>2016</b> , 26, 87-93	3.3	14
281	Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial. <i>Modern Rheumatology</i> , <b>2016</b> , 26, 15-23	3.3	36



280	Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 504-11	4.1	95
279	Evaluation of golimumab for the treatment of patients with active rheumatoid arthritis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2016</b> , 12, 319-26	5.5	3
278	Efficacy of linagliptin and teneligliptin for glycemic control in type 2 diabetic patients with chronic kidney disease: assessment by continuous glucose monitoring; a pilot study. <i>Diabetology International</i> , <b>2016</b> , 7, 368-374	2.3	4
277	Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice. <i>Modern Rheumatology</i> , <b>2016</b> , 26, 850-856	3.3	13
276	Post-hoc analysis showing better clinical response with the loading dose of certolizumab pegol in Japanese patients with active rheumatoid arthritis. <i>Modern Rheumatology</i> , <b>2016</b> , 26, 473-80	3.3	7
275	Clinically relevant radiographic progression in joint destruction in RA patients with abnormal MMP-3 or high levels of CRP despite 1-year treatment with infliximab. <i>Modern Rheumatology</i> , <b>2016</b> , 26, 807-812	3.3	6
274	Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity-results from the ENCOURAGE study, a prospective, international, multicenter randomized study. <i>Modern Rheumatology</i> , <b>2016</b> , 26, 651-61	3.3	19
273	Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 1321-7	2.4	32
272	The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naïve early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 75-83	2.4	66
271	Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of the randomized GO-FORTH trial. <i>Modern Rheumatology</i> , <b>2016</b> , 26, 481-90	3.3	11
270	Prevention of joint destruction in patients with high disease activity or high C-reactive protein levels: Post hoc analysis of the GO-FORTH study. <i>Modern Rheumatology</i> , <b>2016</b> , 26, 323-30	3.3	6
269	Spontaneous Differentiation of Human Mesenchymal Stem Cells on Poly-Lactic-Co-Glycolic Acid Nano-Fiber Scaffold. <i>PLoS ONE</i> , <b>2016</b> , 11, e0153231	3.7	39
268	Pancreas-protective effect of rituximab for acute-onset type 1 diabetes in the honeymoon period: a case report. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , <b>2016</b> , 2016, 160020	1.4	3
267	Current concepts in the management of rheumatoid arthritis. <i>Korean Journal of Internal Medicine</i> , <b>2016</b> , 31, 210-8	2.5	50
266	Overexpression of Peroxiredoxin 4 Affects Intestinal Function in a Dietary Mouse Model of Nonalcoholic Fatty Liver Disease. <i>PLoS ONE</i> , <b>2016</b> , 11, e0152549	3.7	26
265	Excess Visceral Adipose Tissue Worsens the Vascular Endothelial Function in Patients with Type 2 Diabetes Mellitus. <i>Internal Medicine</i> , <b>2016</b> , 55, 3091-3095	1.1	8
264	The changing landscape of biosimilars in rheumatology. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 974-82		124
263	Response to: 'Denosumab, cortical bone and bone erosion in rheumatoid arthritis' by Rossini et al. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, e71	2.4	2

262	Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 1917-1923	2.4	69
261	Adalimumab discontinuation in patients with early rheumatoid arthritis who were initially treated with methotrexate alone or in combination with adalimumab: 1 year outcomes of the HOPEFUL-2 study. <i>RMD Open</i> , <b>2016</b> , 2, e000189	5.9	17
260	Usefulness of nailfold videocapillaroscopy for systemic sclerosis. <i>Inflammation and Regeneration</i> , <b>2016</b> , 36, 5	10.9	4
259	Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with Rheumatoid arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 983-990	2.4	111
258	Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 1428-37	2.4	166
257	Chemical JAK inhibitors for the treatment of rheumatoid arthritis. <i>Expert Opinion on Pharmacotherapy</i> , <b>2016</b> , 17, 2215-2225	4	15
256	Effectiveness of abatacept for patients with Sjögren's syndrome associated with rheumatoid arthritis. An open label, multicenter, one-year, prospective study: ROSE (Rheumatoid Arthritis with Orencia Trial toward Sjögren's syndrome Endocrinopathy) trial. <i>Modern Rheumatology</i> , <b>2016</b> , 26, 891-899	3.3	30
255	Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies. <i>International Journal of Rheumatic Diseases</i> , <b>2016</b> , 19, 1216-1225	2.3	18
254	Psoriatic arthritis in Japan: difference in clinical features and approach to precision medicine. <i>Clinical and Experimental Rheumatology</i> , <b>2016</b> , 34, 49-52	2.2	14
253	Clinical, radiographic and functional efficacy of abatacept in routine care for rheumatoid arthritis patients: Abatacept Leading Trial for RA on Imaging Remission (ALTAIR) study. <i>Clinical and Experimental Rheumatology</i> , <b>2016</b> , 34, 834-841	2.2	3
252	Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , <b>2015</b> , 25, 817-24	3.3	62
251	A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with different anti-tumor necrosis factor therapies: A retrospective observational study. <i>Modern Rheumatology</i> , <b>2015</b> , 25, 344-9	3.3	14
250	Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study. <i>Modern Rheumatology</i> , <b>2015</b> , 25, 514-21	3.3	93
249	Activation of Syk in peripheral blood B cells in patients with rheumatoid arthritis: a potential target for abatacept therapy. <i>Arthritis and Rheumatology</i> , <b>2015</b> , 67, 63-73	9.5	39
248	Increased Syk phosphorylation leads to overexpression of TRAF6 in peripheral B cells of patients with systemic lupus erythematosus. <i>Lupus</i> , <b>2015</b> , 24, 695-704	2.6	16
247	Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside. <i>Journal of Biochemistry</i> , <b>2015</b> , 158, 173-9	3.1	55
246	Relevance of lymphocyte subsets to B cell-targeted therapy in systemic lupus erythematosus. <i>International Journal of Rheumatic Diseases</i> , <b>2015</b> , 18, 208-18	2.3	17
245	Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus. <i>Cardiovascular Diabetology</i> , <b>2015</b> , 14, 25	8.7	32

244	Efficacy and safety of abatacept for patients with Sjögren's syndrome associated with rheumatoid arthritis: rheumatoid arthritis with orencia trial toward Sjögren's syndrome Endocrinopathy (ROSE) trial-an open-label, one-year, prospective study-Interim analysis of 32 patients for 24 weeks. <i>Modern Rheumatology</i> , <b>2015</b> , 25, 187-93	3.3	30
243	Amplification of IL-21 signalling pathway through Bruton's tyrosine kinase in human B cell activation. <i>Rheumatology</i> , <b>2015</b> , 54, 1488-97	3.9	27
242	Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 799-809	4.1	33
241	Assessment of risks of pulmonary infection during 12 months following immunosuppressive treatment for active connective tissue diseases: a large-scale prospective cohort study. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 614-22	4.1	7
240	Serum 14-3-3 $\sigma$ level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab. <i>Arthritis Research and Therapy</i> , <b>2015</b> , 17, 280	5.7	21
239	Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 389-95	2.4	122
238	Low complements and high titre of anti-Sm antibody as predictors of histopathologically proven silent lupus nephritis without abnormal urinalysis in patients with systemic lupus erythematosus. <i>Rheumatology</i> , <b>2015</b> , 54, 405-12	3.9	36
237	Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan. <i>Rheumatology</i> , <b>2015</b> , 54, 683-91	3.9	35
236	A multi-biomarker disease activity score for monitoring rheumatoid arthritis. <i>Current Biomarker Findings</i> , <b>2015</b> , 69		2
235	Histamine inhibits differentiation of skin fibroblasts into myofibroblasts. <i>Biochemical and Biophysical Research Communications</i> , <b>2015</b> , 463, 434-9	3.4	12
234	Early response to certolizumab pegol predicts long-term outcomes in patients with active rheumatoid arthritis: results from the Japanese studies. <i>Modern Rheumatology</i> , <b>2015</b> , 25, 11-20	3.3	11
233	Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry. <i>Arthritis Research and Therapy</i> , <b>2015</b> , 17, 74	5.7	42
232	Combination therapy for early rheumatoid arthritis: a treatment holiday perspective. <i>Expert Review of Clinical Pharmacology</i> , <b>2015</b> , 8, 115-22	3.8	2
231	Contribution of the Interleukin-6/STAT-3 Signaling Pathway to Chondrogenic Differentiation of Human Mesenchymal Stem Cells. <i>Arthritis and Rheumatology</i> , <b>2015</b> , 67, 1250-60	9.5	59
230	Disease control by regulation of P-glycoprotein on lymphocytes in patients with rheumatoid arthritis. <i>World Journal of Experimental Medicine</i> , <b>2015</b> , 5, 225-31	0.4	13
229	Human mesenchymal stem cells as a tool for joint repair in rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , <b>2015</b> , 33, S58-62	2.2	23
228	Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events. <i>Rheumatology</i> , <b>2014</b> , 53, 914-8	3.9	31
227	A case of teriparatide-induced severe hypophosphatemia and hypercalcemia. <i>Journal of Bone and Mineral Metabolism</i> , <b>2014</b> , 32, 601-4	2.9	9

226	IL-6-accelerated calcification by induction of ROR2 in human adipose tissue-derived mesenchymal stem cells is STAT3 dependent. <i>Rheumatology</i> , <b>2014</b> , 53, 1282-90	3.9	36
225	Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus. <i>Journal of Diabetes Investigation</i> , <b>2014</b> , 5, 313-9	3.9	71
224	Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib. <i>Expert Opinion on Pharmacotherapy</i> , <b>2014</b> , 15, 103-13	4	14
223	Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 536-43	2.4	74
222	Prophylaxis for Pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study. <i>Arthritis Research and Therapy</i> , <b>2014</b> , 16, R43	5.7	41
221	Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Oencia( ) as Biological Intensive Treatment for RA (ORBIT) study. <i>Modern Rheumatology</i> , <b>2014</b> , 24, 754-62	3.3	12
220	Systemic lupus erythematosus: prediction by MRI of the subsequent development of brain lesions. <i>Academic Radiology</i> , <b>2014</b> , 21, 617-23	4.3	1
219	The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 2192-8	2.4	98
218	The risk of serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors decreased over time: a report from the registry of Japanese rheumatoid arthritis patients on biologics for long-term safety (REAL) database. <i>Rheumatology International</i> , <b>2014</b> , 34, 1729-36	3.6	9
217	Local delivery of mesenchymal stem cells with poly-lactic-co-glycolic acid nano-fiber scaffold suppress arthritis in rats. <i>PLoS ONE</i> , <b>2014</b> , 9, e114621	3.7	18
216	The possible mode of action of Tofacitinib, a JAK inhibitor. <i>Inflammation and Regeneration</i> , <b>2014</b> , 34, 129-133	10.9	1
215	Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2014</b> , 99, 2599-607	5.6	100
214	Efficacy and safety of reducing duration of infliximab infusion. <i>Modern Rheumatology</i> , <b>2014</b> , 24, 275-80	3.3	3
213	Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial. <i>Modern Rheumatology</i> , <b>2014</b> , 24, 552-60	3.3	31
212	Study on the safety and efficacy of tocilizumab, an anti-IL-6 receptor antibody, in patients with rheumatoid arthritis complicated with AA amyloidosis. <i>Modern Rheumatology</i> , <b>2014</b> , 24, 405-9	3.3	22
211	Abatacept inhibits radiographic progression in patients with rheumatoid arthritis: a retrospective analysis of 6 months of abatacept treatment in routine clinical practice. The ALTAIR study. <i>Modern Rheumatology</i> , <b>2014</b> , 24, 42-51	3.3	8
210	Acquiring chondrocyte phenotype from human mesenchymal stem cells under inflammatory conditions. <i>International Journal of Molecular Sciences</i> , <b>2014</b> , 15, 21270-85	6.3	20
209	Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors. <i>Modern Rheumatology</i> , <b>2014</b> , 24, 399-404	3.3	12

208	Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 15-23	4.1	131
207	Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of 7740 patients. <i>Modern Rheumatology</i> , <b>2014</b> , 24, 390-8	3.3	63
206	Tofacitinib, a JAK inhibitor, inhibits human B cell activation in vitro. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 2213-5	2.4	29
205	Intensive intervention can lead to a treatment holiday from biological DMARDs in patients with rheumatoid arthritis. <i>Drugs</i> , <b>2014</b> , 74, 2129-39	12.1	11
204	Low levels of 1,5-anhydro-D-glucitol are associated with vascular endothelial dysfunction in type 2 diabetes. <i>Cardiovascular Diabetology</i> , <b>2014</b> , 13, 99	8.7	11
203	Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study. <i>Modern Rheumatology</i> , <b>2014</b> , 24, 734-43	3.3	8
202	Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study. <i>Modern Rheumatology</i> , <b>2014</b> , 24, 725-33	3.3	8
201	Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial. <i>Rheumatology</i> , <b>2014</b> , 53, 904-13	3.9	24
200	Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial. <i>Modern Rheumatology</i> , <b>2014</b> , 24, 715-24	3.3	37
199	The non-canonical Wnt5a/Ror2 signaling pathway in bone metabolism. <i>Inflammation and Regeneration</i> , <b>2014</b> , 34, 103-108	10.9	1
198	Effects of raloxifene on lipid and bone metabolism in postmenopausal women with type 2 diabetes. <i>Journal of Bone and Mineral Metabolism</i> , <b>2013</b> , 31, 89-95	2.9	12
197	A case of multiple brown tumors with primary hyperparathyroidism. <i>Journal of Bone and Mineral Metabolism</i> , <b>2013</b> , 31, 123-7	2.9	13
196	Dopamine D2-like receptor signaling suppresses human osteoclastogenesis. <i>Bone</i> , <b>2013</b> , 56, 1-8	4.7	36
195	Is it possible to withdraw biologics from therapy in rheumatoid arthritis?. <i>Clinical Therapeutics</i> , <b>2013</b> , 35, 2028-35	3.5	19
194	Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study. <i>Arthritis Research and Therapy</i> , <b>2013</b> , 15, R135	5.7	32
193	Efficacy of combination of Ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes. <i>Lipids in Health and Disease</i> , <b>2013</b> , 12, 137	4.4	28
192	Successful treatment of osteomalacia caused by renal tubular acidosis associated with Sjögren's syndrome. <i>Modern Rheumatology</i> , <b>2013</b> , 23, 401-405	3.3	4
191	Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. <i>Arthritis and Rheumatism</i> , <b>2013</b> , 65, 559-70		402



190	Efficacy of $\alpha$ -glucosidase inhibitors combined with dipeptidyl-peptidase-4 inhibitor (alogliptin) for glucose fluctuation in patients with type 2 diabetes mellitus by continuous glucose monitoring. <i>Journal of Diabetes Investigation</i> , <b>2013</b> , 4, 393-8	3.9	11
189	A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study. <i>Rheumatology</i> , <b>2013</b> , 52, 1202-7	3.9	65
188	Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus. <i>Cardiovascular Diabetology</i> , <b>2013</b> , 12, 1	8.7	164
187	Effects of pravastatin, atorvastatin, and rosuvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia. <i>Diabetology International</i> , <b>2013</b> , 4, 117-125	2.3	5
186	Clinical characteristics and risk factors for <i>Pneumocystis jirovecii</i> pneumonia in patients with rheumatoid arthritis receiving adalimumab: a retrospective review and case-control study of 17 patients. <i>Modern Rheumatology</i> , <b>2013</b> , 23, 1085-93	3.3	9
185	Abatacept inhibits radiographic progression in patients with rheumatoid arthritis: a retrospective analysis of 6 months of abatacept treatment in routine clinical practice. The ALTAIR study. <i>Modern Rheumatology</i> , <b>2013</b> , 1	3.3	
184	Next stage of RA treatment: is TNF inhibitor-free remission a possible treatment goal?. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72 Suppl 2, ii124-7	2.4	38
183	Janus kinase inhibitors in autoimmune diseases. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72 Suppl 2, ii111-5	2.4	255
182	Prevention of joint destruction by tacrolimus in patients with early rheumatoid arthritis: a post hoc analysis of a double-blind, randomized, placebo-controlled study. <i>Modern Rheumatology</i> , <b>2013</b> , 23, 1045-1052	3.3	7
181	No increased mortality in patients with rheumatoid arthritis treated with biologics: results from the biologics register of six rheumatology institutes in Japan. <i>Modern Rheumatology</i> , <b>2013</b> , 23, 945-952	3.3	19
180	Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 1488-95	2.4	43
179	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 482-92	2.4	87
178	Clinical characteristics and risk factors for <i>Pneumocystis jirovecii</i> pneumonia in patients with rheumatoid arthritis receiving adalimumab: a retrospective review and case-control study of 17 patients. <i>Modern Rheumatology</i> , <b>2013</b> , 23, 1085-1093	3.3	18
177	Safety and effectiveness of 6 months' etanercept monotherapy and combination therapy in Japanese patients with rheumatoid arthritis: effect of concomitant disease-modifying antirheumatic drugs. <i>Journal of Rheumatology</i> , <b>2013</b> , 40, 1658-68	4.1	10
176	Validation of different sets of criteria for the diagnosis of Sjögren's syndrome in Japanese patients. <i>Modern Rheumatology</i> , <b>2013</b> , 23, 219-225	3.3	21
175	Activation of Wnt5a-Ror2 signaling associated with epithelial-to-mesenchymal transition of tubular epithelial cells during renal fibrosis. <i>Genes To Cells</i> , <b>2013</b> , 18, 608-19	2.3	31
174	JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical. <i>Modern Rheumatology</i> , <b>2013</b> , 23, 415-424	3.3	43
173	Antihypertensive and metabolic effects of high-dose olmesartan and telmisartan in type 2 diabetes patients with hypertension. <i>Endocrine Journal</i> , <b>2013</b> , 60, 563-70	2.9	12



172	Dermal mast cell density in fingers reflects severity of skin sclerosis in systemic sclerosis. <i>Modern Rheumatology</i> , <b>2013</b> , 23, 1151-1157	3.3	12
171	IL-17 inhibits chondrogenic differentiation of human mesenchymal stem cells. <i>PLoS ONE</i> , <b>2013</b> , 8, e79463.	3.7	38
170	Successful treatment of osteomalacia caused by renal tubular acidosis associated with Sjögren's syndrome. <i>Modern Rheumatology</i> , <b>2013</b> , 23, 401-5	3.3	2
169	Prevention of joint destruction by tacrolimus in patients with early rheumatoid arthritis: a post hoc analysis of a double-blind, randomized, placebo-controlled study. <i>Modern Rheumatology</i> , <b>2013</b> , 23, 1045-52	3.3	1
168	JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical. <i>Modern Rheumatology</i> , <b>2013</b> , 23, 415-24	3.3	22
167	Dermal mast cell density in fingers reflects severity of skin sclerosis in systemic sclerosis. <i>Modern Rheumatology</i> , <b>2013</b> , 23, 1151-7	3.3	7
166	4. Drugs Targeting Intracellular Molecule: JAK Inhibitor and Syk Inhibitor. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , <b>2013</b> , 44, 23-27	0	
165	Regulatory role of mesenchymal stem cells in osteoclast differentiation. <i>Inflammation and Regeneration</i> , <b>2013</b> , 33, 217-222	10.9	
164	Role of JAKs in myeloid cells and autoimmune diseases. <i>Inflammation and Regeneration</i> , <b>2013</b> , 33, 131-135.	10.9	
163	Discontinuation of biologics in patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , <b>2013</b> , 31, S22-7	2.2	84
162	Treatment strategy based on targeting P-glycoprotein on peripheral lymphocytes in patients with systemic autoimmune disease. <i>Clinical and Experimental Nephrology</i> , <b>2012</b> , 16, 102-8	2.5	22
161	Cell-autonomous role of TGF $\beta$ and IL-2 receptors in CD4+ and CD8+ inducible regulatory T-cell generation during GVHD. <i>Blood</i> , <b>2012</b> , 119, 5575-83	2.2	36
160	Pneumocystis jirovecii pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors. <i>Modern Rheumatology</i> , <b>2012</b> , 22, 849-858	3.3	36
159	Signal transduction inhibitors for the treatment of rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , <b>2012</b> , 14,	5.7	78
158	Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. <i>Modern Rheumatology</i> , <b>2012</b> , 22, 498-508	3.3	72
157	Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial. <i>Modern Rheumatology</i> , <b>2012</b> , 22, 382-393	3.3	51
156	Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity. <i>Modern Rheumatology</i> , <b>2012</b> , 22, 814-822	3.3	27
155	Structural damages disturb functional improvement in patients with rheumatoid arthritis treated with etanercept. <i>Modern Rheumatology</i> , <b>2012</b> , 22, 186-194	3.3	5

154	A case of catastrophic antiphospholipid antibody syndrome complicated with systemic lupus erythematosus, double positive for anti-cardiolipin/β <sub>2</sub> glycoprotein I and anti-phosphatidylserine/prothrombin autoantibodies. <i>Modern Rheumatology</i> , <b>2012</b> , 22, 769-73	3.3	2
153	Interleukin-1β induces differentiation of human mesenchymal stem cells into osteoblasts via the Wnt-5a/receptor tyrosine kinase-like orphan receptor 2 pathway. <i>Arthritis and Rheumatism</i> , <b>2012</b> , 64, 3355-63		112
152	Amplification of Toll-like receptor-mediated signaling through spleen tyrosine kinase in human B-cell activation. <i>Journal of Allergy and Clinical Immunology</i> , <b>2012</b> , 129, 1594-601.e2	11.5	26
151	Telmisartan at 80 mg/day increases high-molecular-weight adiponectin levels and improves insulin resistance in diabetic patients. <i>Advances in Therapy</i> , <b>2012</b> , 29, 635-44	4.1	24
150	Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis. <i>Arthritis Care and Research</i> , <b>2012</b> , 64, 1125-34	4.7	31
149	The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-β and interleukin-17 production by human CD4+ T cells. <i>Arthritis and Rheumatism</i> , <b>2012</b> , 64, 1790-8		146
148	Phenotypic changes of lymphocyte in a patient with IgG4-related disease after corticosteroid therapy. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 2058-9	2.4	9
147	Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 817-24	2.4	88
146	Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). <i>Modern Rheumatology</i> , <b>2012</b> , 22, 327-338	3.3	36
145	Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 1820-6	2.4	45
144	Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. <i>Modern Rheumatology</i> , <b>2012</b> , 22, 21-30	3.3	1070
143	B cell or T cell-dominant recurrence after rituximab therapy in patients with SLE. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 1749-50	2.4	8
142	Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , <b>2012</b> , 24, 319-26	5.3	38
141	A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. <i>Modern Rheumatology</i> , <b>2012</b> , 22, 1-14	3.3	552
140	A case of catastrophic antiphospholipid antibody syndrome complicated with systemic lupus erythematosus, double positive for anti-cardiolipin/β <sub>2</sub> glycoprotein I and anti-phosphatidylserine/prothrombin autoantibodies. <i>Modern Rheumatology</i> , <b>2012</b> , 22, 769-773	3.3	2
139	Structural damages disturb functional improvement in patients with rheumatoid arthritis treated with etanercept. <i>Modern Rheumatology</i> , <b>2012</b> , 22, 186-94	3.3	1
138	A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. <i>Modern Rheumatology</i> , <b>2012</b> , 22, 1-14	3.3	277
137	Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). <i>Modern Rheumatology</i> , <b>2012</b> , 22, 327-38	3.3	21

136	Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. <i>Modern Rheumatology</i> , <b>2012</b> , 22, 21-30	3.3	619
135	Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity. <i>Modern Rheumatology</i> , <b>2012</b> , 22, 814-22	3.3	17
134	Mesenchymal stem cells: A new treatment tool for rheumatoid arthritis. <i>Inflammation and Regeneration</i> , <b>2012</b> , 32, 188-192	10.9	0
133	Efficacité de l'etanercept dans une cirrhose biliaire primitive associée à une polyarthrite rhumatoïde. <i>Revue Du Rhumatisme (Edition Francaise)</i> , <b>2011</b> , 78, 589-590	0.1	
132	Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety. <i>Journal of Rheumatology</i> , <b>2011</b> , 38, 1258-64	4.1	114
131	Recent progress in small molecular products for the treatment of joint and bone diseases: an over view. <i>Inflammation and Regeneration</i> , <b>2011</b> , 31, 341-343	10.9	
130	JAK inhibitor: tofacitinib, a new disease modifying anti-rheumatic drug. <i>Inflammation and Regeneration</i> , <b>2011</b> , 31, 349-353	10.9	1
129	Pericarditis induced by prophylactic administration of isoniazid in a patient with rheumatoid arthritis. <i>Joint Bone Spine</i> , <b>2011</b> , 78, 99-100	2.9	1
128	Successful treatment of primary biliary cirrhosis with etanercept in a patient with rheumatoid arthritis. <i>Joint Bone Spine</i> , <b>2011</b> , 78, 535-6	2.9	9
127	Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. <i>Arthritis Care and Research</i> , <b>2011</b> , 63, 1150-8	4.7	221
126	Human mesenchymal stem cells inhibit osteoclastogenesis through osteoprotegerin production. <i>Arthritis and Rheumatism</i> , <b>2011</b> , 63, 1658-67		58
125	Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). <i>Modern Rheumatology</i> , <b>2011</b> , 21, 122-133	3.3	57
124	Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , <b>2011</b> , 21, 343-351	3.3	78
123	Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 2148-51	2.4	125
122	Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B cell depletion therapy with rituximab. <i>Journal of Rheumatology</i> , <b>2011</b> , 38, 633-41	4.1	50
121	Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from the JESMR study. <i>Journal of Rheumatology</i> , <b>2011</b> , 38, 1585-92	4.1	68
120	Efficacy of combination therapy of anti-TNF- $\alpha$ antibody infliximab and methotrexate in refractory entero-Beht disease. <i>Modern Rheumatology</i> , <b>2011</b> , 21, 184-191	3.3	60
119	Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDs: multicenter, double-blind, parallel-group trial. <i>Modern Rheumatology</i> , <b>2011</b> , 21, 458-468	3.3	21

118	Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients--REACTION 52-week study. <i>Rheumatology</i> , <b>2011</b> , 50, 1908-15	3.9	69
117	The REAL database reveals no significant risk of serious infection during treatment with a methotrexate dose of more than 8 mg/week in patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , <b>2011</b> , 21, 444-448	3.3	14
116	Jak and Syk: Emerging their relevance to the treatment of inflammatory diseases. <i>Inflammation and Regeneration</i> , <b>2011</b> , 31, 237-244	10.9	6
115	Denosumab for the treatment of joint and bone diseases. <i>Inflammation and Regeneration</i> , <b>2011</b> , 31, 344-348	10.9	1
114	Efficacy of combination therapy of anti-TNF- $\alpha$ antibody infliximab and methotrexate in refractory entero-Beht's disease. <i>Modern Rheumatology</i> , <b>2011</b> , 21, 184-91	3.3	40
113	Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , <b>2011</b> , 21, 343-51	3.3	36
112	Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDs--a multicenter, double-blind, parallel-group trial. <i>Modern Rheumatology</i> , <b>2011</b> , 21, 458-68	3.3	10
111	Etanercept overcomes P-glycoprotein-induced drug resistance in lymphocytes of patients with intractable rheumatoid arthritis. <i>Modern Rheumatology</i> , <b>2010</b> , 20, 139-146	3.3	19
110	Tacrolimus, a calcineurin inhibitor, overcomes treatment unresponsiveness mediated by P-glycoprotein on lymphocytes in refractory rheumatoid arthritis. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 512-20	4.1	49
109	Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 1286-91	2.4	205
108	Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial. <i>Modern Rheumatology</i> , <b>2010</b> , 20, 531-538	3.3	56
107	Galectin-9 induces osteoblast differentiation through the CD44/Smad signaling pathway. <i>Biochemical and Biophysical Research Communications</i> , <b>2010</b> , 394, 317-22	3.4	36
106	C5a promotes migration, proliferation, and vessel formation in endothelial cells. <i>Inflammation Research</i> , <b>2010</b> , 59, 659-66	7.2	32
105	Advanced glycation end products increase endothelial permeability through the RAGE/Rho signaling pathway. <i>FEBS Letters</i> , <b>2010</b> , 584, 61-6	3.8	86
104	Mast cell-derived tryptase inhibits apoptosis of human rheumatoid synovial fibroblasts via rho-mediated signaling. <i>Arthritis and Rheumatism</i> , <b>2010</b> , 62, 952-9		39
103	Etanercept overcomes P-glycoprotein-induced drug resistance in lymphocytes of patients with intractable rheumatoid arthritis. <i>Modern Rheumatology</i> , <b>2010</b> , 20, 139-46	3.3	9
102	Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial. <i>Modern Rheumatology</i> , <b>2010</b> , 20, 531-8	3.3	33
101	Effects of anti-TNF-alpha antibody infliximab in refractory entero-Beht's disease. <i>Rheumatology</i> , <b>2009</b> , 48, 1012-3	3.9	41

100	Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. <i>Journal of Rheumatology</i> , <b>2009</b> , 36, 898-906	4.1	153
99	Usefulness of initial histological features for stratifying Sjogren's syndrome responders to mizoribine therapy. <i>Rheumatology</i> , <b>2009</b> , 48, 1279-82	3.9	17
98	Antagonizing dopamine D1-like receptor inhibits Th17 cell differentiation: preventive and therapeutic effects on experimental autoimmune encephalomyelitis. <i>Biochemical and Biophysical Research Communications</i> , <b>2008</b> , 373, 286-91	3.4	109
97	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2). <i>Modern Rheumatology</i> , <b>2008</b> , 18, 146-152	3.3	58
96	Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. <i>Modern Rheumatology</i> , <b>2008</b> , 18, 460-464	3.3	41
95	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J). <i>Modern Rheumatology</i> , <b>2008</b> , 18, 447-454	3.3	38
94	Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy. <i>Journal of Rheumatology</i> , <b>2008</b> , 35, 2249-54	4.1	41
93	Reply to Dr Pollono. <i>Endocrine Journal</i> , <b>2008</b> , 55, 949	2.9	
92	Interaction of galectin-9 with lipid rafts induces osteoblast proliferation through the c-Src/ERK signaling pathway. <i>Journal of Bone and Mineral Research</i> , <b>2008</b> , 23, 278-86	6.3	28
91	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2). <i>Modern Rheumatology</i> , <b>2008</b> , 18, 146-52	3.3	28
90	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J). <i>Modern Rheumatology</i> , <b>2008</b> , 18, 447-54	3.3	19
89	Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. <i>Modern Rheumatology</i> , <b>2008</b> , 18, 460-4	3.3	24
88	Activation signal transduction by beta1 integrin in T cells from patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 56, 1559-68		23
87	Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. <i>Annals of the Rheumatic Diseases</i> , <b>2007</b> , 66, 470-5	2.4	214
86	Enhanced effect of high-dose leukocytapheresis using a large filter in rheumatoid arthritis. <i>Modern Rheumatology</i> , <b>2007</b> , 17, 481-485	3.3	12
85	A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. <i>Modern Rheumatology</i> , <b>2007</b> , 17, 191-197	3.3	93
84	Leflunomide inhibits PDK1/Akt pathway and induces apoptosis of human mast cells. <i>Journal of Immunology</i> , <b>2007</b> , 179, 6479-84	5.3	35
83	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). <i>Modern Rheumatology</i> , <b>2007</b> , 17, 28-32	3.3	56



82	Treatment of inflammatory immunologic disease 4. B cell targeting therapy using the anti-CD20 antibody rituximab in inflammatory autoimmune diseases. <i>Internal Medicine</i> , <b>2007</b> , 46, 1313-5	1.1	16
81	Efficacy and safety of mizoribine for the treatment of Sjögren's syndrome: a multicenter open-label clinical trial. <i>Modern Rheumatology</i> , <b>2007</b> , 17, 464-469	3.3	30
80	Small GTPase Rho signaling is involved in beta1 integrin-mediated up-regulation of intercellular adhesion molecule 1 and receptor activator of nuclear factor kappaB ligand on osteoblasts and osteoclast maturation. <i>Biochemical and Biophysical Research Communications</i> , <b>2007</b> , 356, 279-85	3.4	13
79	A case of life-threatening refractory polychondritis successfully treated with combined intensive immunosuppressive therapy with methotrexate. <i>Modern Rheumatology</i> , <b>2007</b> , 17, 144-147	3.3	9
78	Acetylation of an Ets Transcription Factor PU.1 Suppresses Its Transcriptional Activity.. <i>Blood</i> , <b>2007</b> , 110, 2402-2402	2.2	
77	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). <i>Modern Rheumatology</i> , <b>2007</b> , 17, 28-32	3.3	32
76	A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. <i>Modern Rheumatology</i> , <b>2007</b> , 17, 191-7	3.3	49
75	Efficacy and safety of mizoribine for the treatment of Sjögren's syndrome: a multicenter open-label clinical trial. <i>Modern Rheumatology</i> , <b>2007</b> , 17, 464-9	3.3	17
74	Enhanced effect of high-dose leukocytapheresis using a large filter in rheumatoid arthritis. <i>Modern Rheumatology</i> , <b>2007</b> , 17, 481-5	3.3	6
73	Attempt to correct abnormal signal transduction in T lymphocytes from systemic lupus erythematosus patients. <i>Autoimmunity Reviews</i> , <b>2006</b> , 5, 143-4	13.6	11
72	Fragmented hyaluronan induces transcriptional up-regulation of the multidrug resistance-1 gene in CD4+ T cells. <i>Journal of Biological Chemistry</i> , <b>2006</b> , 281, 38089-97	5.4	18
71	Glycated albumin and cross-linking of CD44 induce scavenger receptor expression and uptake of oxidized LDL in human monocytes. <i>Biochemical and Biophysical Research Communications</i> , <b>2006</b> , 339, 846-51	3.4	9
70	Increased expression levels of monocyte CCR2 and monocyte chemoattractant protein-1 in patients with diabetes mellitus. <i>Biochemical and Biophysical Research Communications</i> , <b>2006</b> , 344, 780-5	3.4	57
69	Anti-CD20 and other novel biotherapies for systemic lupus erythematosus. <i>APLAR Journal of Rheumatology</i> , <b>2006</b> , 9, 413-418		3
68	Growth suppression of human mast cells expressing constitutively active c-kit receptors by JNK inhibitor SP600125. <i>Genes To Cells</i> , <b>2006</b> , 11, 983-92	2.3	10
67	Small GTP-binding protein Rho-mediated signaling promotes proliferation of rheumatoid synovial fibroblasts. <i>Arthritis Research</i> , <b>2005</b> , 7, R476-84		13
66	Human urinary trypsin inhibitor bolus infusion improved severe interstitial pneumonia in mixed connective tissue disease. <i>Modern Rheumatology</i> , <b>2005</b> , 15, 374-380	3.3	5
65	Clinical relevance of the expression of P-glycoprotein on peripheral blood lymphocytes to steroid resistance in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2005</b> , 52, 1676-83		69



64	Overcoming treatment unresponsiveness mediated by P-glycoprotein overexpression on lymphocytes in refractory active systemic lupus erythematosus. <i>Modern Rheumatology</i> , <b>2005</b> , 15, 28-32	3.3	15
63	Osteoblasts and osteoclasts in bone remodeling and inflammation. <i>Inflammation and Allergy: Drug Targets</i> , <b>2005</b> , 4, 325-8		246
62	Glucocorticoid-induced osteoporosis: skeletal manifestations of glucocorticoid use and 2004 Japanese Society for Bone and Mineral Research-proposed guidelines for its management. <i>Modern Rheumatology</i> , <b>2005</b> , 15, 163-168	3.3	8
61	Human urinary trypsin inhibitor bolus infusion improved severe interstitial pneumonia in mixed connective tissue disease. <i>Modern Rheumatology</i> , <b>2005</b> , 15, 374-80	3.3	1
60	Effects of oxygen therapy during sleep in chronic dialysis patients with sleep-disordered breathing. <i>Nihon Toseki Igakkai Zasshi</i> , <b>2005</b> , 38, 1187-1194	0.3	
59	Overcoming treatment unresponsiveness mediated by P-glycoprotein overexpression on lymphocytes in refractory active systemic lupus erythematosus. <i>Modern Rheumatology</i> , <b>2005</b> , 15, 28-32	3.3	9
58	Glucocorticoid-induced osteoporosis: skeletal manifestations of glucocorticoid use and 2004 Japanese Society for Bone and Mineral Research-proposed guidelines for its management. <i>Modern Rheumatology</i> , <b>2005</b> , 15, 163-8	3.3	5
57	Transcriptional regulation of multidrug resistance-1 gene by interleukin-2 in lymphocytes. <i>Genes To Cells</i> , <b>2004</b> , 9, 1265-73	2.3	49
56	Macrophage inflammatory protein-1alpha induces hypercalcemia in adult T-cell leukemia. <i>Journal of Bone and Mineral Research</i> , <b>2004</b> , 19, 1105-11	6.3	36
55	Acro-Osteolysis and Symphalangism Mutations. <i>Journal of Bone and Mineral Research</i> , <b>2004</b> , 20, 160-160	6.3	
54	Genome-wide linkage analysis of type 2 diabetes mellitus reconfirms the susceptibility locus on 11p13-p12 in Japanese. <i>Journal of Human Genetics</i> , <b>2004</b> , 49, 629-634	4.3	18
53	Severe hypercalcemia and hyponatremia associated with calcipotriol for treatment of psoriasis. <i>Journal of Bone and Mineral Metabolism</i> , <b>2004</b> , 22, 159-62	2.9	12
52	Induction of RANKL expression and osteoclast maturation by the binding of fibroblast growth factor 2 to heparan sulfate proteoglycan on rheumatoid synovial fibroblasts. <i>Arthritis and Rheumatism</i> , <b>2004</b> , 50, 2450-8		57
51	Adult-onset idiopathic progressive acro-osteolysis with proximal symphalangism. <i>Journal of Bone and Mineral Research</i> , <b>2004</b> , 19, 165-7	6.3	4
50	Expression of the Chk2 Gene Is Downregulated in Hodgkin's Lymphoma Cell Lines Via Epigenetic Mechanisms.. <i>Blood</i> , <b>2004</b> , 104, 429-429	2.2	
49	Etidronate prevents high dose glucocorticoid induced bone loss in premenopausal individuals with systemic autoimmune diseases. <i>Journal of Rheumatology</i> , <b>2004</b> , 31, 163-6	4.1	24
48	Beta1 integrin/focal adhesion kinase-mediated signaling induces intercellular adhesion molecule 1 and receptor activator of nuclear factor kappaB ligand on osteoblasts and osteoclast maturation. <i>Journal of Biological Chemistry</i> , <b>2003</b> , 278, 45368-74	5.4	58
47	Inter- and intracellular signaling in secondary osteoporosis. <i>Journal of Bone and Mineral Metabolism</i> , <b>2003</b> , 21, 61-6	2.9	12

46	beta1 integrin-mediated signaling induces intercellular adhesion molecule 1 and Fas on rheumatoid synovial cells and Fas-mediated apoptosis. <i>Arthritis and Rheumatism</i> , <b>2003</b> , 48, 1239-48		30
45	Crosslinking of CD44 on human osteoblastic cells upregulates ICAM-1 and VCAM-1. <i>FEBS Letters</i> , <b>2003</b> , 539, 45-50	3.8	28
44	Monocyte chemoattractant protein-1 induces scavenger receptor expression and monocyte differentiation into foam cells. <i>Biochemical and Biophysical Research Communications</i> , <b>2003</b> , 305, 380-5	3.4	44
43	Efficacy of mizoribine treatment in patients with Sjögren's syndrome: an open pilot trial. <i>Modern Rheumatology</i> , <b>2003</b> , 13, 339-45	3.3	12
42	Severe skin ulceration associated with Wegener's granulomatosis: successful treatment with hyperbaric oxygen and prostaglandin E1. <i>Modern Rheumatology</i> , <b>2003</b> , 13, 346-9	3.3	
41	Efficacy of mizoribine treatment in patients with Sjögren's syndrome: an open pilot trial. <i>Modern Rheumatology</i> , <b>2003</b> , 13, 339-345	3.3	1
40	Severe skin ulceration associated with Wegener's granulomatosis: successful treatment with hyperbaric oxygen and prostaglandin E1. <i>Modern Rheumatology</i> , <b>2003</b> , 13, 346-349	3.3	
39	Hypoxia-inducible factor-1alpha induces cell cycle arrest of endothelial cells. <i>Genes To Cells</i> , <b>2002</b> , 7, 143-9	3.3	52
38	Autocrine induction of the human pro-IL-1beta gene promoter by IL-1beta in monocytes. <i>Journal of Immunology</i> , <b>2002</b> , 168, 1984-91	5.3	55
37	H-Ras/mitogen-activated protein kinase pathway inhibits integrin-mediated adhesion and induces apoptosis in osteoblasts. <i>Journal of Biological Chemistry</i> , <b>2002</b> , 277, 21446-52	5.4	35
36	Clinical implication of cyclosporin for systemic autoimmune diseases: relevance to multidrug resistance. <i>Japanese Journal of Clinical Immunology</i> , <b>2002</b> , 25, 110-114		1
35	Pneumocystis carinii pneumonia in patients with connective tissue diseases. <i>Japanese Journal of Clinical Immunology</i> , <b>2002</b> , 25, 310-318		
34	Fractalkine, a CX3C-chemokine, functions predominantly as an adhesion molecule in monocytic cell line THP-1. <i>Immunology and Cell Biology</i> , <b>2001</b> , 79, 298-302	5	78
33	Down-regulation of alpha6 integrin, an anti-oncogene product, by functional cooperation of H-Ras and c-Myc. <i>Genes To Cells</i> , <b>2001</b> , 6, 337-43	2.3	9
32	CD44 is the physiological trigger of Fas up-regulation on rheumatoid synovial cells. <i>Journal of Immunology</i> , <b>2001</b> , 167, 1198-203	5.3	62
31	CD44 stimulation down-regulates Fas expression and Fas-mediated apoptosis of lung cancer cells. <i>International Immunology</i> , <b>2001</b> , 13, 1309-19	4.9	54
30	Activated platelets and endothelial cell interaction with neutrophils under flow conditions. <i>Internal Medicine</i> , <b>2001</b> , 40, 1085-92	1.1	33
29	The role of chemokines and adhesion molecules in the pathogenesis of rheumatoid arthritis. <i>Drugs of Today</i> , <b>2001</b> , 37, 477-484		20

28	Intercellular adhesion molecule 1 underlies the functional heterogeneity of synovial cells in patients with rheumatoid arthritis: involvement of cell cycle machinery. <i>Arthritis and Rheumatism</i> , <b>2000</b> , 43, 2513-22		8
27	Intercellular adhesion molecule 1 discriminates functionally different populations of human osteoblasts: characteristic involvement of cell cycle regulators. <i>Journal of Bone and Mineral Research</i> , <b>2000</b> , 15, 1912-23	6.3	69
26	Constitutive activation of LIL-Stat in adult T-cell leukemia cells. <i>Blood</i> , <b>2000</b> , 95, 2715-2718	2.2	6
25	Intercellular adhesion molecule-1 (ICAM-1) mediated gene delivery to rheumatoid synovial cells using the Fab fragments of anti-ICAM-1 monoclonal antibody. <i>Japanese Journal of Clinical Immunology</i> , <b>2000</b> , 23, 533-537		1
24	Additive combination of actarit and methotrexate in the treatment of refractory rheumatoid arthritis. <i>Modern Rheumatology</i> , <b>2000</b> , 10, 103-109	3.3	1
23	Activation of leukocyte function-associated antigen-1 on adult T-cell leukemia cells. <i>Leukemia and Lymphoma</i> , <b>1999</b> , 36, 15-23	1.9	12
22	H-Ras signals to cytoskeletal machinery in induction of integrin-mediated adhesion of T cells. <i>Journal of Immunology</i> , <b>1999</b> , 163, 6209-16	5.3	57
21	Heparan sulfate proteoglycan on endothelium efficiently induces integrin-mediated T cell adhesion by immobilizing chemokines in patients with rheumatoid synovitis. <i>Arthritis and Rheumatism</i> , <b>1998</b> , 41, 1365-77		46
20	Induction of expression of MHC-class-II antigen on human thyroid carcinoma by wild-type p53. <i>International Journal of Cancer</i> , <b>1998</b> , 75, 391-5	7.5	10
19	A critical role for cyclin C in promotion of the hematopoietic cell cycle by cooperation with c-Myc. <i>Molecular and Cellular Biology</i> , <b>1998</b> , 18, 3445-54	4.8	40
18	Constitutive Chemokine Production Results in Activation of Leukocyte Function-Associated Antigen-1 on Adult T-Cell Leukemia Cells. <i>Blood</i> , <b>1998</b> , 91, 3909-3919	2.2	64
17	Chemokine and Cellular Adhesion in the Context of Heparan Sulfate Proteoglycan.. <i>Trends in Glycoscience and Glycotechnology</i> , <b>1998</b> , 10, 153-160	0.1	5
16	Constitutive up-regulation of integrin-mediated adhesion of tumor-infiltrating lymphocytes to osteoblasts and bone marrow-derived stromal cells. <i>Cancer Research</i> , <b>1998</b> , 58, 4138-45	10.1	20
15	Chondrocytes are regulated by cellular adhesion through CD44 and hyaluronic acid pathway. <i>Journal of Bone and Mineral Research</i> , <b>1997</b> , 12, 1657-63	6.3	102
14	Distinct phenotype of leukemic T cells with various tissue tropisms. <i>Journal of Immunology</i> , <b>1997</b> , 158, 3822-9	5.3	39
13	Osteoblasts are regulated by the cellular adhesion through ICAM-1 and VCAM-1. <i>Journal of Bone and Mineral Research</i> , <b>1995</b> , 10, 1462-9	6.3	85
12	CD45RB expression defines two interconvertible subsets of human CD4+ T cells with memory function. <i>European Journal of Immunology</i> , <b>1994</b> , 24, 1240-3	6.1	21
11	Differential expression of integrins alpha 6 and alpha 4 determines pathways in human peripheral CD4+ T cell differentiation. <i>Cell Adhesion and Communication</i> , <b>1994</b> , 2, 403-15		7

10	Interleukin-4 induces proliferation of adult T-cell leukemia cells. <i>European Journal of Haematology</i> , <b>1993</b> , 50, 133-40	3.8	9
9	Suppressive effect of interleukin-4 on the differentiation of M1 and HL60 myeloid leukemic cells. <i>Journal of Leukocyte Biology</i> , <b>1993</b> , 54, 133-7	6.5	4
8	Proteoglycans on endothelial cells present adhesion-inducing cytokines to leukocytes. <i>Trends in Immunology</i> , <b>1993</b> , 14, 111-5		382
7	T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-1 beta. <i>Nature</i> , <b>1993</b> , 361, 79-82	50.4	790
6	Lymphocyte interactions with endothelial cells. <i>Trends in Immunology</i> , <b>1992</b> , 13, 106-12		607
5	B-B cell interactions in the spontaneous activation of B cells in autoimmune NZB mice. <i>Microbiology and Immunology</i> , <b>1991</b> , 35, 741-53	2.7	4
4	Suppressive activity of interleukin 4 on the induction of antigen-specific cytotoxic T cells in humans. <i>Japanese Journal of Cancer Research</i> , <b>1991</b> , 82, 585-92		9
3	Inhibitory effect of IL-1 on the TSH dependent growth of rat thyroid cells (FRTL-5). <i>Endocrinologia Japonica</i> , <b>1990</b> , 37, 619-27		4
2	Antiviral and antiproliferative activities of recombinant human interferon alpha 2, beta and gamma on HTLV-I and ATL cells in vitro. <i>Journal of UOEH</i> , <b>1990</b> , 12, 149-61	1.6	6
1	Trans-ancestry genome-wide association study identifies novel genetic mechanisms in rheumatoid arthritis		2